

ALIYA KHAN, MD, FRCPC, FACP, FACE, FASBMR
Metabolic Bone Disease

223-3075 Hospital Gate, Oakville, Ontario L6M 1M1 Tel (905) 844-5677 Fax (905) 844-8966

CURRICULUM VITAE

PERSONAL DATA:

Health: *Excellent*
Marital Status: *Married, 3 children*
Citizenship: *Canadian*
Email: [*aliya@mcmaster.ca*](mailto:aliya@mcmaster.ca)

CURRENT POSITION AND EMPLOYMENT HISTORY:

Date of Initiation

(July 2006 –) *Clinical Professor of Medicine
Divisions of Endocrinology and Metabolism and Geriatric Medicine
McMaster University
Hamilton, Ontario*

(March 2003 –) *Director, Calcium Disorders Clinic
St. Joseph's Healthcare
Hamilton, Ontario*

(July 2015 –) *Director, Fellowship in Metabolic Bone Disease
McMaster University
Hamilton, Ontario*

(July 1993 –) *Director, Bone Research and Education Centre
Suite 223-3075 Hospital Gate
Oakville, Ontario*

(July 1989 –) *Consultant, Department of Medicine
Oakville-Trafalgar Memorial Hospital
Oakville, Ontario*

(July 1999 – June 2006) *Associate Clinical Professor of Medicine, McMaster University*
(July 1993- June 1999) *Assistant Clinical Professor of Medicine, McMaster University*

PROFESSIONAL AFFILIATIONS/ADMINISTRATIVE AND EXECUTIVE POSITIONS:

- *American Association of Clinical Endocrinologists – Member (1993-)*
- *American College of Physicians – Fellow*
- *American College of Endocrinology – Fellow*
- *American Society for Bone and Mineral Research – Member (1993-)*
- *American Society for Bone and Mineral Research – Professional Practice Committee – member (2019-2022)*
- *American Society for Bone and Mineral Research – Ambassador for Canada (2019-)*

- (1982) *Doctorate in Medicine - University of Ottawa*
- (1982) *Licentiate of the Medical Council of Canada*
- (1983) *Diplomat of the National Board of Medical Examiners – Ranked in the 96th percentile*
- (1987) *Diplomat of the American Board of Internal Medicine*
- (1988) *Fellow of the Royal College of Physicians and Surgeons of Canada - Internal Medicine*
- (1989) *St. Michael's Hospital Research Day - Higgins Prize*
- (1990) *Fellow of the Royal College of Physicians and Surgeons of Canada - Geriatric Medicine*
- (1997) *Fellow of the American College of Physicians*
- (2008) *Fellow of the American College of Endocrinology*
- (2011) *Osteoporosis Society of Canada - Ontario Service Award*
- (2011) *International Society for Clinical Densitometry - Clinician Instructor of the Year Award*
- (2012) *Queen Elizabeth II Diamond Jubilee Medal - For Excellence in Clinical Care, Research and Teaching*
- (2014) *International Hypoparathyroidism Association Award for Enhancing Patient Care (Sacramento - June)*
- (2015) *International Society for Clinical Densitometry Supervisor for Young Investigator Award given to Fellow Waleed Hashem for "Atypical Femoral Fractures histomorphometric features" – Supervisor (ISCD Annual Meeting, Illinois - February)*
- (2017) *International Award for Publishing Excellence in Osteoporosis International for the paper "Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus" which was among the journal's top five most downloaded papers in 2016.*
- (2019) *Appointed Canadian Ambassador for American Society of Bone and Mineral Research in May*
- (2019) *Recognized as being in the top 0.1% of the world experts in hyperparathyroidism by Expertscape*
- 2020 – *Selected as Fellow of the American Society For Bone and Mineral Research (ASBMR) in recognition of distinguished accomplishments and contributions to the musculoskeletal field*
- 2020 – *awarded the Lindy Fraser Osteoporosis Canada award for outstanding contributions to research and education*
- 2021 – *supervisor for ASBMR Young Investigator Award given to Fellow Karel Dandurand for "Barakat Syndrome- a mini series"*
- 2022 – *supervisor for Outstanding Abstract for ENDOCRINE society annual meeting given to Fellow Dalal Ali for abstract "Transition From Low Dose Denosumab 30mg to IV Zoledronic Acid: Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Prospective Observational Study"*
- 2023 – *supervisor for C. Wayne Bardin International Travel Award for outstanding abstract for ENDOCRINE society annual meeting given to Fellow Dalal Ali for abstract evaluating genotype phenotype correlations in calcium sensing receptor mutations*
- 2023 – *recipient of the Trailblazer in Science Award by MAX – for outstanding contributions to Scientific advancements in Canada*
- 2024 June 20 – *recipient of the Hamilton Health Sciences Humanitarian Award for dedicated service to Medicine*
- 2024 - *recipient of the Woman Physician of the Year Award by the American College of Physicians (ACP) Ontario Chapter honoring an outstanding woman physician with a distinguished career in areas of exceptional patient care, medical education and/or research.*
- 2024 – *recipient of the ACP Humanitarian of the Year Award given for outstanding contributions to humanism in medicine in 2024.*
- 2024 *Canadian Society of Endocrinology and Metabolism DR. JACQUES GENEST LECTURER AWARD in Halifax Awarded to the individual chosen to deliver the CSEM Award Lecture at the Annual Professional Conference on "Hypoparathyroidism – Advances in Diagnosis and Management"*
- 2024- *recipient of the OrtoMed Medal – X1X Societa Italiana di Ortopedia e Medicina , Florence, Italy Dec 12-14, 2024 for outstanding scientific contributions to metabolic bone disease*
- 2025- *recipient of the King Charles 111 Medal for major contributions to advancement in Medicine and Science*

RESEARCH ACTIVITIES:

1997-1999

A study comparing Raloxifene Hydrochloride and Alendronate Sodium to Placebo in the Treatment of Postmenopausal Women with Osteoporosis.

- Co-Investigator of multicenter trial
Funding: Eli Lilly Canada \$5,000
- 1998-2003 *A double blind randomized placebo controlled trial of alendronate in primary hyperparathyroidism.
Lead Principle investigator of International multicentre trial
Funding: Merck Frosst Canada & National Institutes of Health - \$101,750 Canadian, \$212,000 for US site*
- 1998-2000 *Tolerability of drug therapy in post-menopausal osteoporosis.
Principle investigator
Funding: Merck Frosst Canada \$ 5,000*
- 1999-2000 *Efficacy of bisphosphonate therapy in post-menopausal osteoporosis.
Principle investigator
Funding: Merck Frosst Canada \$5,000*
- 1999-2000 *Acquisition of normative database of peripheral bone mass in Canadian women.
Co-investigator
Funding: Norland Canada \$3,000*
- July'00- July'02 *Randomized parallel group study assessing quality of life, safety and resource utilization in postmenopausal women treated with alendronate or nasal spray calcitonin.
Co-investigator
Funding: Novartis Canada - \$25,000 for 2 years*
- July'00–July'01 *A multicentre open-label randomized crossover preference study of oral alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis.
Co-investigator
Funding :Merck Frosst Canada \$28,000*
- Mar 2000-2004 *An 18-month double blind placebo controlled phase III trial with a 12-month interim analysis of the effect of recombinant human parathyroid hormone (ALX 1-11) on fracture incidence in postmenopausal osteoporosis.
Co-investigator
Funding: NPS Allelix - \$195,650 for 18 months*
- July 2000 *Assessment of peripheral bone mass measurement in individuals with primary hyperparathyroidism.
Principle investigator
Funding: Norland Canada - \$3,000 for 1 year*
- 2004 *A multinational open-label safety extension study with intravenous bolus injections of Zoledronic acid (ZOL446H) in the treatment of osteoporosis
Co-investigator
Funding approved: Duke University - \$153,540 for 1 year*
- 2002-2004 *18-month open-label extension study (OLES) of the safety and efficacy of recombinant human parathyroid hormone, rhPTH(1-84), ALX1-11 in women with postmenopausal osteoporosis who participated in protocol ALX1-11-93001. CL1-11-002
Funding: NPS Allelix - \$149,433 for 18 months*
- 2002-2004 *Multicenter double-blind randomized placebo-controlled study to evaluate the safety and efficacy of Zoledronic acid in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D (CZOL446H2301)
Funding approved: Norartis Pharma Canada Inc. - \$5,000 for 3 years*

- 2004-2005 *Fosamax Actonel Comparison Trials International: A randomized, double-blind, double-dummy, parallel-group, multicentre study to evaluate and compare the effects of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis*
Co-investigator
Funding: Merck Frosst Canada - \$81,995 for 1 year, Extension Phase – 1 additional year
- 2004 *An epidemiologic study of the prevalence of vitamin D insufficiency and deficiency in postmenopausal women on therapy to treat or prevent osteoporosis*
Co-investigator
Funding: Merck Frosst Canada - \$21,350 for 1 year
- 2004 *A randomized controlled trial of risedronate once monthly in comparison to daily dosing over 2 years.*
Co-investigator
Funding: Aventis Pharmaceuticals - \$130,120 for 2 years
- Sept 2005 *A Randomized, Double-Blind, Placebo-Controlled, Single Centre Study to Evaluate the Effects of Alendronate on Bone Mineral Density in Perimenopausal Women with Low Bone Mineral Density*
Principle Investigator
Funding: Medical School Research Grants program, Merck Frosst Canada, \$178,000 for 12 months
- 2006 *The effects of Teriparatide on bone mineral density and serum calcium in postmenopausal osteoporosis.*
Principle Investigator
Funding: Eli Lilly Canada \$10,000
- 2007 *Osteonecrosis of the jaw in Ontario: Bisphosphonates and Other Risk factors*
Principle Investigator
Merck Frosst, Proctor and Gamble Pharmaceuticals,
Novartis Pharmaceuticals,
Calcium Disorders Clinic, St. Joseph's
\$30,000
- 2008 *Supervisor for student Shelley Pallan - awarded a CIHR research award for research on "Persistent and recurrent hypercalcemia after minimally-invasive parathyroidectomy for primary hyperparathyroidism."*
- 2008 *A Randomized Double-Blind Placebo -Controlled Pivotal Study to investigate the use of NPSP 558, a Recombinant Human Parathyroid Hormone rhPTH (1-84) for the treatment of adult subjects with hypoparathyroidism*
Funding source: NPS pharmaceuticals
Co-investigator
- 2009 *A Cost Effectiveness Analysis evaluating the use of NPSP 558, a Recombinant Human Parathyroid Hormone rhPTH(1-84) with hypoparathyroidism.*
Funding source NPS pharmaceuticals Total Clinical Budget \$125,000
Co-investigator
- 2009 *Cochrane Review of bisphosphonates*
Co-investigator
- 2010 *A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy.*
Sponsor Amgen. Total Clinical Budget - \$114,550.
Co-investigator

- 2011 *Prospective Observational Study to Evaluate Persistence With Prolia (Denosumab) in Postmenopausal Women with Osteoporosis in Routine Clinical Practice.*
Co-investigator
Sponsor Amgen
Total Clinical Budget - \$13,392.
- 2012 *A Multicenter, International, Randomized, Double-blind, placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of AMG 785 Treatment in Postmenopausal Women With Osteoporosis.*
Sponsor Amgen. Total Clinical Budget - \$209,473.76
Co-investigator
- 2012 *Medication Use Patterns, Treatment Satisfactions, and Inadequate Control of Osteoporosis Study (MUSIC-OS)*
Sponsor Merck and Co., Inc. Total Clinical Budget - \$80,000.00
Co-investigator
- 2012 *Prospective Observational Study to Evaluate Persistence With Prolia (Denosumab) in Postmenopausal Women With Osteoporosis in Routine clinical Practice*
Sponsor Amgen
Co-investigator
- 2013 *Estimating the Burden of Osteoporosis-Related Fractures in Terms of Health-Related Quality of Life, Utility, and Resource Use (BOOST), Protocol Number 0822 078-00*
Sponsor Merck. Total Clinical Budget - \$13,200
- 2013 *20070337 Placebo-controlled Fracture Study in Postmenopausal Women with Osteoporosis (FRAME)*
Sponsor Amgen, Total Clinical Budget -\$300,000
- 2014 *Canadian National Hypoparathyroidism Registry: Evaluating Presentation, Etiology, Complications and Treatment of Hypoparathyroidism In Canada*
Principle Investigator
- 2015 *PARADIGM Physicians Advancing Disease Knowledge in Hypoparathyroidism): A natural history registry for patients with chronic hypoparathyroidism*
Canadian Principle Investigator of a multicenter study
Sponsor – Shire
Total Budget \$100,000
- 2016 *Teriparatide After Atypical Femoral Fracture*
Co-investigator
Sponsor UHN and Lilly
- 2017 *Osteoporosis Treatment Rates post Hip Fracture in a Community Hospital*
Principle Investigator
- 2017 *Canadian National Hypoparathyroidism Burden of Illness study – Principle Investigator*
Shire Budget \$100,000
- 2017 *Efficacy of low dose Denosumab in maintaining bone mineral density in postmenopausal women with osteoporosis: a real world, prospective observational study*
Principle Investigator
- 2017 *Osteoporosis Treatment Rates post Hip Fracture in a Community Hospital*

Principle Investigator

- 2018 *SHP634-101 An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects with Hypoparathyroid*
Principle Investigator of multinational study
Sponsor – Shire –Takeda \$300,000
- 2019 *SHP634-404 An Open Label Study investigating the Safety and Efficacy of rhPTH(1-84) in Subjects with Hypoparathyroidism*
Canadian Principle Investigator of a multicenter study
Sponsor – Shire –Takeda
- 2019 *SHP634-401 A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]*
Canadian Principle Investigator of a multicenter study
Sponsor – Takeda
- 2019 *A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicentre Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men with Osteoporosis*
Canadian Investigator of a multicenter study
Sponsor – Radius
- 2019 *PaTH Forward: A Phase 2, Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism*
International PI of a multicenter study
Sponsor – Ascendis
- 2019 *Personalizing Osteoporosis Care: Clinical & Genetic Risk Factors for AFFs*
Sponsor – Radius
Co-Investigator
- 2020 *A Randomized double blind multiple ascending oral dose study to evaluate the safety , tolerability pharmacokinetics and pharmacodynamics of PCO371 in patients with hypoparathyroidism*
Sponsor – Chugai Pharmaceuticals Co. Ltd
Co- investigator
- 2021 *PaTH Forward _ A Phase 3 multicenter Randomized placebo controlled trial of Transcon PTH administered subcutaneously daily in adults with hypoparathyroidism*
Canadian PI of a multicenter study
Sponsor – Ascendis
- 2021 *Disease Monitoring Program for X-Linked Hypophosphatemia*
Co-investigator
Sponsor – Ultragenyx
- 2021 *Pharmacokinetics and Pharmacodynamics of single dose administration of TC PTH*
Co-investigator
Sponsor – Ascendis

- 2023 CALIBRATE study sponsored by Calcilytix Therapeutics, Inc., a BridgeBio Company. This Phase 3 open-label study evaluating the efficacy, safety, and tolerability of encalceret in comparison to standard of care (SoC) in participants with ADH1
Principle Investigator
- 2023 A phase 3 multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eneboparatide (AZP-3601), A parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)
Study sponsor Amolyt
Principle Investigator
- 2023 A PHASE 3 MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENEBOPARATIDE (AZP-3601), A PARATHYROID HORMONE RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC HYPOPARATHYROIDISM (CALYPSO)
Study sponsor Amolyt
Principle Investigator
- 2024 A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 (Recombinant Alkaline Phosphatase) Administered Subcutaneously in Adolescent (12 to < 18 years of age) and Adult Participants with Hypophosphatasia Who Have Not Previously Been Treated with Asfotase Alfa
- 2024 An International Observational Registry Study to Further Describe Long-term Safety and Effectiveness of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva (FOP)
- 2024 A Phase 1b, single ascending dose, randomized, double-blind study to evaluate the safety, tolerability, and activity of SAR439459 in adults with osteogenesis imperfecta

LIFETIME PUBLICATIONS: NOT INCLUDING CONFERENCE PAPERS or ABSTRACTS

A. Peer Reviewed

1. "Osteoporosis associated with Pregnancy - Case Report and Review" By: A. A. Khan, M. Ahmed, K.P.H. Pritzker Endocrine Practice July 1995
2. "Diagnosis and Management of Primary Hyperparathyroidism"- A review By: A. A. Khan Endocrine Practice January 1997
3. "Use of Cyclical Etidronate and the Prevention of Non-Vertebral Fractures" Letter to Editor By: D. Kendler and A. A. Khan British Journal of Rheumatology Vol. 37 No.11, November 1998 pp 1253-1254
4. Primary Hyperparathyroidism – Pathophysiology and Impact on Bone By: A. A. Khan, J. Bilezikian Canadian Medical Association Journal, July 2000, 103(2), pp 184-187
5. The Healthy Woman – Advances in Osteoporosis Research By: A. A. Khan Advanced Healthcare Strategies, July 2000
6. Skeletal Effects of Primary Hyperparathyroidism By: Z. Syed, A. A. Khan Endocrine Practice September 2000, Vol. 6, No 5, pp 385-388
7. Advances in the Prevention of Post-menopausal Osteoporosis By: A. A. Khan Mature Medicine, October 2000 pp 153-156
8. An Evidence-Based Review of the Management of Osteoporosis By: Brown, J., Fortier, M., Khan, A. A., Rowe, T. Journal of Obstetrics & Gynecology of Canada JOGC, April 2001 pp 2-7
9. Canadian Consensus on Menopause and Osteoporosis By: Yuen, C.K., Kendler, D, Khan, A.A., Brown, J., Fortier, M. Journal of Obstetrics and Gynecology of Canada, JOGC Oct, 2001 pp 1-11
10. A Double-Blind Randomized Placebo-Controlled Trial of Alendronate in Primary Hyperparathyroidism By: Khan, AA, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, Ho AYY, Motagally Z, Rubin M, Silverberg SJ, Standish TI, Syed ZA Journal of Bone and Mineral Research Vol. 16, Suppl.1 September 2001, F465, S226.

11. Alendronate in Primary Hyperparathyroidism By: Khan, A.A., Bilezikian, J., Kung, A., et al. *Journal Bone Mineral Research*, October 2001
12. Bone Densitometry: Applications and Limitations By: Khan, A.A., Syed, Z *Journal of Obstetrics and Gynaecology Canada*, JOGC June 2002 Volume 24, 6, Pp 1-9
13. A Double-Blind Randomized Placebo-Controlled Trial of Alendronate in Primary Hyperparathyroidism By: Khan AA, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, Ho AYY, Motagally Z, Rubin M, Silverberg SJ, Standish TI, Syed ZA *Journal of Bone and Mineral Research* Vol 17, Suppl.1 September 2002, S1165-1169.
14. Standards and Guidelines for Performing Central Dual X-Ray Densitometry from the Canadian Panel of International Society for Clinical Densitometry By: Khan AA, Brown J, Faulkner K, Kendler D, Lentle B, Leslie W, Miller P, Nicholson L, Olszynski WP, Watts NB *Journal of Clinical Densitometry* Vol 5. No. 3, 247-257, Fall 2002.
15. The 2002 Canadian Bone Densitometry Recommendations: Take-home Messages By: Khan AA, Brown JP, Kendler DL, Leslie WD, Lentle BC, Lewiecki M, Miller PD, Nicholson RL, Olszynski WP, Watts NB *CMAJ* November 12, 2002; 167(10), 1141-1145.
16. 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. By: Brown JP, Josse JG for the Scientific Advisory Council of the Osteoporosis Society of Canada (Biomarkers by A.A. Khan) *CMAJ* Nov 12, 2002; 167(S1-S33).
17. Standards and Guidelines for Performing Central Dual X-Ray Densitometry from the Canadian Panel of International Society for Clinical Densitometry By: Khan AA, Brown J, Faulkner K, Kendler D, Lentle B, Leslie W, Miller PD, Nicholson L, Olszynski WP and Watts NB, *Journal of Clinical Densitometry* Vol. 5, No. 4, 435-445, Winter 2002
18. Advances in Osteoporosis Therapy: 2003 Update of Practical Guidelines By: Khan AA *Canadian Family Physician* 2003; 49:441-447
19. Peak Performance; New Guidelines Set Standard for BMD Measurement Osteoporosis Update, official journal of the Osteoporosis Society of Canada Fall 2003 Vol. 7 No. 4
20. What about bisphosphonates for a patient with hypertension and osteoporosis? Answered by Aliya Khan, *The Canadian Journal of CME*, Vol. 15, No. 9 September 2003
21. A Double Blind Randomized Placebo Controlled Trial of Alendronate in Primary Hyperparathyroidism Plenary Poster Presentation – Abstract 663 *ASMBR 25th Annual Meeting*, September 19-23, 2003, Minneapolis, MN
22. Position Paper: Asymptomatic Primary Hyperparathyroidism – Standards and Guidelines for Diagnosis and Management in Canada Khan AA, Hanley DA, O'Brien CJ, Pasioka J, Ste-Marie LG, Rotstein LE, Rosen I, Young JEM, Josse RG, Bilezikian JP *Endocrine Practice* Vol. 9 No. 5 September/October 2003 pp 400-405.
23. "Statistics Can Affect Treatment Decisions" Letter to the Editor by Aliya Khan December 2003 *Canadian Family Physician* Vol.: 49, pp 1587-1588
24. "Standards and Guidelines for Performing Central Dual X-Ray Densitometry in Premenopausal Women, Men, and Children from the Canadian Panel of the International Society of Clinical Densitometry" Khan AA, Bachrach L, Brown JP, Hanley DA, Josse RG, Kendler DL, Leib ES, Lentle BC, Leslie WD, Lewiecki M, Miller PD, Nicholson RL, O'Brien C, Olszynski WP, Theriault MYD, Watts NB, *JCD*, Vol. 7, no. 1, 51-63, 2004.
25. "Bone Densitometry in Premenopausal Women" Khan AA, Syed Z, *JCD*, Vol. 7, no. 1, 85-92, 2004.
26. Position Statement: The Writing Group for the ISCD Position Development Conference by the Writing Group" (Aliya Khan) *Diagnosis of osteoporosis in men, premenopausal women and children*, *JCD* Vol. 7, #1, 13-15, 2004.
27. Bisphosphonates in osteoporosis; Ask the Expert – by Aliya Khan, *Canadian Journal of CME*, Feb 2004, p 44.
28. Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial Khan AA, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, Ho AYY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA, *J Clin Endocrinol Metab*, July 2004, 89(7):3319-3325.
29. "Vitamin D Inadequacy is Highly Prevalent Among North American Women Treated for Osteoporosis" by Holick MF, Siris ES, Binkley N, Beard MK, Khan AA, Katzer JT, Chen E, de Papp AE. *JBMR*, October, 2004

30. "Prevalence of Vitamin D Inadequacy Among Postmenopausal North American Women Receiving Osteoporosis Therapy" by Holick MF, Siris ES, Binkley N, Beard MK, Khan AA, Katzer JT, Petruschke RA, Chen E, de Papp AE, JCEM, March 2005, pp 2004-2364
31. "Management of Low Bone Mineral Density in Premenopausal Women" by Aliya Khan JOGC, April 2005, pp 345-349
32. Recommendations for bone mineral density reporting in Canada. Siminoski K, Leslie WD, Frame H, Hodsmann A, Josse RG, Khan A, Lentle BC, Levesque J, Lyons DJ, Tarulli G, Brown JP. Can Assoc Radiol J 2005; 56: 178-188
33. "Anabolic Agents: A New Chapter in the Management of Osteoporosis" By Abdul Wahab Khan, Aliya Khan, JOGC, February 2006, pp 136-141
34. "Bone Mineral Density Assessment in Premenopausal Women", by Aliya Khan, Zeba Syed Future Medicine: Women's Health, 2006, Vol. 2, no. 4, pp 1-7
35. Standards for Performing DXA in Individuals with Secondary Causes of Osteoporosis from the Canadian Panel of International Society for Clinical Densitometry A.A. Khan, D.A. Hanley, J.P. Bilezikian, N. Binkley, J.P. Brown, A.B. Hodsmann, R.G. Josse, D.L. Kendler, E.M. Lewiecki, P.D. Miller, W.P. Olszynski, S.M. Petak, Z.A. Syed, D. Theriault, N.B. Watts. JCD, Vol. 9, no. 1, 47-57, 2006
36. "Alendronate in Primary Hyperparathyroidism: Efficacy in Men and Premenopausal Women" Khan AA, Dubois S, Standish TIM, Syed ZA, Osteoporosis International, Vol. 17, S190
37. "Premenopausal Women and Low Bone Density" Aliya Khan, Canadian Family Physician, 2006. Vol. 52, 743-747.
38. "Drug Therapy for Postmenopausal Osteoporosis: A Review" Faizan Amin, Moin Khan, A.A. Khan, Advances in Osteoporotic Fracture Management (AOFM). September 2006, Vol.4 No.4
39. "Management of Osteoporosis in men: an update and case example" Aliya A. Khan, Anthony B. Hodsmann, Alexandra Papaioannou, David Kendler, Jacques P. Brown, Wojciech P. Olszynski Canadian Medical Association Journal, January 2007, 176(3), pp 345-348
40. "Recognizing and Reporting Vertebral Fractures: Reducing the Risk of Future Osteoporotic Fractures" Brian C. Lentle, Jacques P. Brown, Aliya A. Khan, William D. Leslie, Jacques Levesque, David J. Lyons, Kerry Siminoski, Giuseppe Tarulli, Robert G. Josse, Anthony Hodsmann. Canadian Association of Radiologists Journal, (CARJ) Vol. 58, February 2007, pp 27-36
41. Standards and Guidelines for Technologists Performing Central Dual-Energy X-Ray Absorptiometry Aliya A. Khan, Anita Colquhoun, David A. Hanley Lawrence G. Jankowski, Robert G. Josse, David L. Kendler, Brian Lentle, William D. Leslie, E. Michael Lewiecki, Elaine O'Neill, Stephen Robertson, Zeba A. Syed, S. Bobo Tanner and Dave Webster JCD, Vol.10, no.2, 189-195, 2007
42. "Middle East and North Africa consensus on osteoporosis" G. Maalouf, M.H. Gannagé-Yared, J. Ezzedine, B. Larijani, S. Badawi, A. Rached, L. Zakroui, B. Masri, E. Azar, E. Saba, R. Nammari, G. Adib, H. Abou Samra, Z. Alrawi, S. Salman, K. El Muntasser, R. Tarseen, W. El Kharousi, M. Al-Lamki, A.N. Alothman, N. Almarzook, M. El Dessouki, R. Sulaimani, J. Saleh, A.R. Suhaili, A. Khan, P. Delmas, E. Seeman Journal of Musculoskeletal and Neuronal Interactions (JMNI), Volume 7, Number 2, June 2007
43. "Hyperparathyroidism: High calcium and PTH raise suspicions" By Jazmin Marlinga, AA Khan Parkhurst Exchange, Volume 15, Number 1, January 2007, p72-73
44. "Recommendations for Bone Mineral Density Reporting in Canada: A Shift to Absolute Fracture Risk Assessment" By: Kerry Siminoski, William D. Leslie, Heather Frame, Anthony Hodsmann, Robert G. Josse, Aliya Khan, Brian C. Lentle, Jacques Levesque, David J. Lyons, Giuseppe Tarulli, and Jacques P. Brown. Journal of Clinical Densitometry; vol. 10, no. 2, 120-123, 2007
45. "Cancer treatment—related bone loss: a review and synthesis of the literature" By: M.N. Khan and A.A. Khan. Current Oncology, Volume 15, Supplement 1, 2008, S30-S40
46. "Osteonecrosis of the Jaw: New Developments in an Old Disease" By: A.A Khan. (J.Rheumatol Feb 2008; 35: 1-3)
47. "Canadian Consensus Practice Guidelines for Bisphosphonate Associated Osteonecrosis of the Jaw," By: Aliya A. Khan, George K.B. Sandor, Edward Dore, Archibald D. Morrison, Mazen Alsahli, Faizan Amin, Edmond Peters, David A. Hanley, Sultan R. Chaudry, David W. Dempster, Francis H. Glorieux, Alan J. Neville, Reena M. Talwar, Cameron M. Clokie, Majd Al

- Mardini, Terri Paul, Sundeep Khosla, Robert G. Josse, Susan Sutherland, David K. Lam, Robert P. Carmichael, Nick Blanas, David Kendler, Steven Petak, Louis Georges St-Marie, Jacque Brown, A. Wayne Evans, Lorena Rios, and Juliet E. Compston *Journal of Rheumatology*, 2008 Jul; 35(7):1391-7
48. "Dual-Energy X-Ray Absorptiometry Technical Issues: The 2007 ISCD Official Positions," Christine Simonelli, Robert A. Adler, Glen M. Blake, JoAnn P. Caudill, Aliya Khan, Ed Leib, Michael Maricic, Jerilynn C. Prior, Sergio Ragi Eis, Cliff Rosen, David L. Kendler, *Journal of Clinical Densitometry*, Vol 11, Jan-Mar 2008
 49. "Osteonecrosis of the Jaw- relationship to bisphosphonate use: commentary and perspective," By: Aliya Khan, *Aging Health*, Vol 4, No.3, PP 217-219, June 2008
 50. "Risk factors for low BMD in healthy men age 50 years or older: a systematic review," By: A.Papaioannou, C.C. Kennedy, A. Cranney, G.Hawker, J.P. Brown, S.M.Kaiser, W.D. Leslie, C.J. M. O'Brien, A.M.Sawka, A.Khan, K.Siminoski, G.Tarulli, D.Webster, J. McGowan, J.D.Adachi, *International Osteoporosis Foundation and National Osteoporosis Foundation*, June 2008
 51. "Osteonecrosis of the jaw: Summary and perspective" By: Aliya Khan, *Osteoporosis Update*, Vol 12, No. 2, 2008
 52. Raloxifene and the Perimenopause by .AA. Khan *Osteoporosis Update*, official journal of the Osteoporosis Society of Canada Fall 2001 Vol. 5 No. 4
 53. "Bisphosphonate-associated Osteonecrosis of the Jaw," By: Aliya Khan, *Canadian Family Physician*, Vol 54, PP 1019-1021, July 2008
 54. Aliya A. Khan, George K.B. Sándor, Edward Dore, Archibald D. Morrison, Mazen Alsahli, Faizan Amin, Edmund Peters, David A. Hanley, Sultan R. Chaudry, David W. Dempster, Francis H. Glorieux, Alan J. Neville, Reena M. Talwar, Cameron M. Clokie, Majd Al Mardini, Terri Paul, Sundeep Khosla, Robert G. Josse, Susan Sutherland, David K. Lam, Robert P. Carmichael, Nick Blanas, David Kendler, Steven Petak, Louis Georges St-Marie, Jacques Brown, A. Wayne Evans, Lorena Rios, and Juliet E. Compston *Canadian Consensus Practice Guidelines for Bisphosphonate Associated Osteonecrosis of the Jaw J Rheumatol July 2008 35:1391-7*
 55. Mohammed O. Rahman, Aliya Khan, *Osteoporosis Screening and Assessment of Fracture Risk, GERIATRICS & AGING* • November/December 2008 • Volume 11, Number 10
 56. Khan A. Osteonecrosis of the jaw: new developments in an old disease [editorial]. *J Rheumatol* 2008; 35:547-9.
 57. Aliya A. Khan, John P. Bilezikian, John T. Potts, Jr Guest Editors for the Third International Workshop on Asymptomatic Primary Hyperparathyroidism EDITORIAL: The Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism Revisited. *J Clin Endocrinol Metab* 2009 94: 333-334
 58. John P. Bilezikian, Aliya A. Khan, John T. Potts, Jr on behalf of the Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism SUMMARY STATEMENT: Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop *J Clin Endocrinol Metab* 2009 94: 335-339
 59. Aliya Khan, Andrew Grey, and Dolores Shoback. Medical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop *J Clin Endocrinol Metab* 2009 94: 373-381
 60. Khan AA. Letter to the editor. Osteonecrosis of the jaw. 2009 *Journal of Rheumatology*
 61. Reid RL, Blake J, Abramson B, Khan AA, Senikas V, Fortier M. Menopause and osteoporosis. January 2009. *JOGC Clinical Practice Guideline SOGC Supplement 1- 48*
 62. Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Lentle B, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Mardini MA, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, Ste-Marie LG, Brown J, Evans AW, Rios L, Compston JE, Bisphosphonate associated osteonecrosis of the jaw. *J Rheumatol*. 2009 Mar; 36(3): 478-90
 63. Papaioanno A, Kennedy CC, Cranney A, Hawker G, Brown JP, Kaiser SM, Leslie WD, O'Brien CJM, Sawka AM, Khan A, Siminoski K, Tarulli G, Webster D, McGowan J, Adachi JD. Risk factors for low BMD in healthy men age 50 years or older: a systematic review. *Osteoporosis Int* 2009 Apr; 20(4):507-18.
 64. Asymptomatic PHPT: A commentary on the revised guidelines Khan A, Bilezikian J, Potts J., *Endocrine Practice* Vol. 15. No. 6, July – August 2009, pp. 1 – 5

65. Aliya A. Khan, John P. Bilezikian, Annie Kung, Zeba A. Syed, Sacha J. Dubois, Timothy Standish. Alendronate Therapy in Men with Primary Hyperparathyroidism, *Endocrine Practice* Nov/Dec. 2009, Vol. 15 No.: 1-9
66. Osteonecrosis of the jaw and bisphosphonates, Aliya Khan, Commissioned editorial, *BMJ*, 2010 Feb;340:c246
67. Asymptomatic Primary Hyperparathyroidism - Commentary on Current Management, Aliya Khan, *Journal of Clinical Densitometry*, 2010 Oct-Dec;13(4):321-3. doi: 10.1016/j.jocd.2010.07.002
68. Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care, Pallan S, Khan A, *Can Fam Physician*, 2011 Feb;57(2):184-9.
69. Primary Hyperparathyroidism, Hafsa Al-Azem, Aliya Khan, *CMAJ*, 2011 Jul 12;183(10):E685-9. doi: 10.1503/cmaj.090675. Epub 2011 Apr 26
70. Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons, Aliya A. Khan, Lorena P. Rios, George K.B. Sandor, Nazir Khan, Edmund Peters, Mohammed O. Rahman, Cameron M.L. Clokie, Edward Dore and Sacha Dubois, *Journal of Rheumatology*, 2011 Jul;38(7):1396-402. doi: 10.3899/jrheum.100221. Epub 2011 Apr 15.
71. FRAX Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry and International Osteoporosis Foundation Position Development Conference, E. Michael Lewiecki, Juliet E. Compston, Paul D. Miller, Jonathan D. Adachi, Judith E. Adams, William D. Leslie, John A. Kanis, Alireza Moayyeri, Robert A. Adler, Didier B. Hans, David L. Kendler, Adolfo Diez-Perez, Marc-Antoine Krieg, Basel K. Masri, Roman R. Lorenc, Douglas C. Bauer, Glen M. Blake, Robert G. Josse, Patricia Clark, and Aliya A. Khan, *Journal of Clinical Densitometry*, 2011 Jul;14(3):223-225
72. Hypoparathyroidism in the Adult: Epidemiology, Diagnosis, Pathophysiology, Target-Organ Involvement, Treatment, and Challengers for Future Research, John P. Bilezikian, Aliya Khan, John T. Potts Jr., Maria Luisa Brandi, Bart L. Clarke, Dolores Shoback, Harald Juppner, Pierre D'Amour, John Fox, Lars Rejnmark, Leif Mosekilde, Mishaela R. Rubin, David Dempster, Rachel Gafni, Michael T. Collins, Jim Sliney, and James Sanders, *JBMR* 2011 Oct;26(10):2317-37. doi: 10.1002/jbmr.483
73. Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®, E. Michael Lewiecki, Juliet E. Compston, Paul D. Miller, Jonathan D. Adachi, Judith E. Adams, William D. Leslie, John A. Kanis, Alireza Moayyeri, Robert A. Adler, Didier B. Hans, David L. Kendler, Adolfo Diez-Perez, Marc-Antoine Kireg, Basel K. Masri, Roman R. Lorenc, Douglas C. Bauer, Glen M. Blake, Robert G. Josse, Patricia Clark, Aliya A. Khan, *The International Society for Clinical Densitometry, Journal of Clinical Densitometry: Assessment of Skeletal Health*, 2011;14(3):226-236
74. Hypoparathyroidism – Clinical Diagnosis and Management for the primary care physician, Jeremy Fong and Aliya Khan - *Canadian Family Physician* 2012 Feb;58(2):158-162
75. Hyperparathyroidism – Diagnosis and Management – a Clinical Review, Shelley Pallan, Omair Rahman, Aliya Khan, *British Medical Journal*, 2012 Mar; 344:e1013
76. Hypoparathyroidism: Current therapies for management – A Clinical Review, Hafsa Al- Azem and Aliya Khan, *Best Practice and Research Clinical Endocrinology and Metabolism*, 2012 Aug, 26(4):517-537
77. Evaluation and Management of Skeletal Health in Celiac Disease: Position Statement, Mona A. Founda, Aliya Khan, Muhammed Sultan, Lorena P. Rios and David Armstrong, *Canadian Journal of Gastroenterology*, 2012 Nov;26(11):819-29.
78. Evaluation and Management of Celiac Disease in Osteoporosis: Position Statement, Lorena P. Rios, Aliya Khan, Muhammad Sultan, Mona A. Fouda, Karen McAssey, and David Armstrong, *Canadian Family Physician*, 2012 Nov;26(11):819-29
79. Atypical Femoral Fractures - What you need to know, Madiha Tauqir, and Aliya Khan - *Canadian Family Physician*, 2012 - in press
80. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis, Robert Josse, Aliya Khan, Daniel Ngui, Marla Shapiro, *Current Medical Research and Opinion*, 2013 Mar;29(3):205-16. doi: 10.1185/03007995.2013.763779. Epub 2013 Jan 25

81. Supplement on Primary Hyperparathyroidism - Editorial, Aliya Khan, Maria Luisa Brandi, John T. Potts, and John B. Bilezikian, *Journal of Clinical Densitometry*, 2013 Jan-Mar;16(1):3. doi: 10.1016/j.jocd.2012.11.011. Epub 2013 Jan 5.
82. Medical Management of Primary Hyperparathyroidism, Aliya Khan - *Journal of Clinical Densitometry*, 2013 Jan-Mar;16(1):60-3. doi: 10.1016/j.jocd.2012.11.010.
83. Improving Management of Osteoporosis Through Simple Changes in Reporting Fragility Fractures, Steven Burrell, Heather Frame, S. Nimu Ganguli, Sian E. Iles, Aliya Khan *Canadian Association of Radiologists Journal*, 2013 Nov;64(4):278-80. doi: 10.1016/j.carj.2013.09.001
84. Denosumab, a New Pharmacotherapy Option for Postmenopausal Osteoporosis, Robert Josse, Aliya Khan, Daniel Ngui, Marla Shapiro, *Canadian Medical Research and Opinion*, 2013 Mar;29(3):205-16. doi: 10.1185/03007995.2013.763779. Epub 2013 Jan 25
85. Bisphosphonates for Treatment of Osteoporosis (Clinical Review) Jacques P. Brown, Suzanne Morin, William Leslie, Alexandra Papaioannou, Angela M. Cheung, Kenneth S. Davison, David Goltzman, David Arthur Hanley, Anthony Hodsmann, Robert Josse, Algis Jovaisas, Angela Juby, Stephanie Kaiser, Andrew Karaplis, David Kendler, Aliya Khan, Daniel Ngui, Wojciech Olszynski, Louis-Georges Ste-Marie, Jonathan Adachi, *Canadian Family Physicians*, 2014 Apr; 60:324-333
86. Atypical Femoral Fractures: A Teaching Perspective, Aliya A. Khan, William D. Leslie, Brian Lentle, Sian Iles, Stephanie M. Kaiser, Heather Frame, Steven Burrell, Angela M. Cheung, *Can Assoc Radiol J.*, 2015 May;66(2):102-7. doi: 10.1016/j.carj.2014.01.002.Epub 2014 Jul 19
87. Atypical Femoral Fractures: Radiographic Histomorphometric Features in 19 Patients, Aliya Khan, Angela Cheung, Osama A. Khan, Zohair Rahman, Kenneth Pritzker, Brian Lentle, *Journal of Clinical Densitometry*, 2014 Jul, 17(3): 402-403
88. Medical Management of Primary Hyperparathyroidism of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism Marcocci C, Bollerslev J, Khan AA, Shoback DM. *J Clin Endocrinol Metab*, 2014 Oct;99(10):3607-18. doi: 10.1210/jc.2014-1417. Epub 2014 Aug 27
89. Foundation for Medical Practice Education "Calcium levels when to test and how to handle abnormal results" Educational Module vol22(8). August 2014. Practice Based Learning Program McMaster University
90. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate on Bone Mineral Density and Bone Remodelling in Perimenopausal Women With Low Bone Mineral Density, Khan A, Fortier M, Menopause and Osteoporosis Working Group, Fortier M, Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Graves L, Guthrie B, Johnston S, Khan A, Rowe T, Sodhi N, Wilks P, Wolfman N., *J Obstet Gynaecol Can.*, 2014 Nov 36(11):976-982.
91. Osteoporosis in Menopause, Khan A, Fortier M, Menopause and Osteoporosis Working Group, Fortier M, Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Graves L, Guthrie B, Johnston S, Khan A, Rowe T, Sodhi N, Wilks P, Wolfman N., *J Obstet Gynaecol Can.* 2014 Sep;36(9):839-840.
92. Managing Menopause Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W, Menopause and Osteoporosis Working Group, Fortier M, Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Graves L, Guthrie B, Khan A, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W., *J Obstet Gynaecol Can.* 2014 Sep;36(9):830-833.
93. Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus, Khan A, Morrison A, Hanley D, Felsenberg D, McCauley L, O'Ryan F, Reid I, Ruggiero S, Taguchi A, Tetradis S, Watts N, Brandi M, Peters E, Guise T, Eastell R, Cheung A, Morin S, Masri B, Cooper C, Morgan S, Obermayer-Pietsch B, Langdahl B, Al Dabagh R, Davison K, Kendler D, Sandor G, Josse R, Bhandari M, El Rabbamy M, Plerroz D, Sulimani R, Saunders D, Brown J, Compston J, *J Bone Miner Res.* 2015 Jan;30(1):3-23. doi: 10.1002/jbmr.2405
94. Development of Recommendations for Radiologists Regarding the Evaluation and Management of Osteoporosis When Reporting Major Osteoporotic Fractures in Those Over Age 50, H. Frame, S. Burrell, S. Iles, S. Nimu Ganguli, A. Khan, *Journal of Clinical Densitometry* 2014 Jul; 17(3):420. DOI:10.1016/j.jocd.2014.04.080
95. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery, Aliya Aziz Khan, John Bilezikian, Henry G Bone, Andrey Gurevich,

- Péter Lakatos, Waldemar Misiorowski, Liudmila Rozhinskaya, Marie-Louise Trotman and Miklos Toth, *European Journal of Endocrinology* 2015 May;172(5):527-35. doi: 10.1530/EJE-14-0877. Epub 2015 Jan 30
96. Conference Paper: Effect of Teriparatide on Healing of Incomplete Atypical Femur Fractures Angela M. Cheung, J. D. Adachi, Aliya Khan, Robert Bleakney, *Osteoporosis International*, 2014 Apr;25
 97. Response to Comments on "Diagnosis and Management of Osteoporosis of the Jaw: A Systematic Review and International Consensus, Aliya Khan, Archie Morrison, Salvatore Ruggiero, Sotirios Tetradis, K. Shawn Davison, Edward Peters, Juliet Compston, *Journal of Bone and Mineral Research* 2015 Oct;30(10):1941. doi: 10.1002/jbmr.2593. Epub 2015 Jul 20
 98. Persistence with denosumab therapy among osteoporotic women in the Canadian patient support program Alexandra Papaioannou, Aliya Khan, Andre Belanger, William Bensen, David Kendler, Francois Theoret, Mo Amin, Lee Brekke, Michelle Erdmann, Valery Walker, and Jonathan D. Adachi, *Current Medical Research and Opinion*, 2015 Jun;31(7):1391-401. doi: 10.1185/03007995.2015.1053049. Epub 2015 Jun 9
 99. Bilateral atypical femoral fractures: how much symmetry is there on imaging?, Linda Probyn, Angela M. Cheung, Catherine Lang, Leon Lenchik, Jonathan D. Adachi, Aliya Khan, Robert G. Josse, George Tomlinson, Robert Bleakney, *Skeletal Radiology* 2015 Nov;44(11):1579-84. doi: 10.1007/s00256-015-2212-7. Epub 2015 Jul 14
 100. Osteonecrosis of the jaw: Update for dentists, Archibald Morrison, Aliya Khan, Sotirios Tetradis, Edmund Peters, *CDA Oasis* 2015 Sep;81:f19
 101. Osteonecrosis of the Jaw (ONJ) diagnosis and management in 2015 *Osteoporosis International* A. Khan, A. Morrison, A. Cheung, W. Hashem, J. Compston, 2016 Mar;27(3):853-9. doi: 10.1007/s00198-015-3335-3. Epub 2015 Oct 22.
 102. Presentation of Hypoparathyroidism: Etiologies and Clinical Features, Dolores M. Shoback, John P. Bilezikian, Aline G. Costa, David Dempster, Henning Dralle, Aliya A. Khan, Munro Peacock, Marco Raffaelli, Barbara C. Silva, Rajesh V. Thakker, Tamara Vokes, Roger Bouillon, *JCEM* 2016 Jun;101(6):2300-12. doi: 10.1210/jc.2015-3909. Epub 2016 Mar 4
 103. Management of Hypoparathyroidism: Summary Statement and Guidelines, Maria Luisa Brandi, John P. Bilezikian, Dolores Shoback, Roger Bouillon, Bart Clarke, Rajesh V. Thakker, Aliya Khan, and John T. Potts Jr, *JCEM* Epub 2016 Mar, DOI: 10.1210/jc.2015-3907
 104. A primer on primary hyperparathyroidism John P. Bilezikian¹, Natalie E. Cusano, Aliya A. Khan, Jian-Min Liu, Claudio Marcocci and Francisco Bandeira, *Nature Reviews*, 2016 May;2:1- 16
 105. Atypical Femoral Fracture Alert Program, Aliya A. Khan, Sian Iles, Stephanie M. Kaiser, Linda Probyn, Angela Cheung, Steven Burrell, *Canadian Association of Radiologists Journal* 2016 Jun; 20:1-2. DOI:10.1016/j.carj.2016.04.002
 106. Vitamin D deficiency and biochemical variations among urban Saudi adolescent girls according to season Riad A. Sulimani, MD, FRCPC, Ashry G. Mohammed, MBChB, DrPH, Assim A. Alfadda, FRCPC, FACE, Suliman N. Alshehri, MD, PhD, Abdulaziz M. Al-Othman, MSc, PhD, Nasser M. Al-Daghri, MSc, PhD, David A. Hanley, MD, FRCPC, Aliya A. Khan, FRCPC, FACP. *Saudi Med J*, 2016, volume 37 99) pp 1002- 1008
 107. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and International Consensus. Aliya A. Khan, David A. Hanley, Rene Rizzoli, Jens Bollerslev, J.E.M Young, Lars Rejnmark, Rajesh Thakker, Pierre D'Amour, Terri Paul, Stan Van Uum, M. Zakarea Shrayyef, David Goltzman, Stephanie Kaiser, Natalie E. Cusano, Roger Bouillon, Leif Mosekilde, Annie W. Kung, Sudhaker D. Rao, Sanjay K. Bhadada, Bart L. Clarke, Jian-min Liu, Quan-Yang Duh, E. Michael Lewiecki, Francisco Bandeira, Richard Eastell, Claudio Marcocci, Shonni J. Silverberg, Robert Udelsman, K. Shawn Davison, John T. Potts Jr, Maria Luisa Brandi, and John P. Bilezikian, *Osteoporos Int* (2017) 28:1–19
 108. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ Aliya A. Khan, Archie Morrison, David L. Kendler, Rene Rizzoli, David A. Hanley, Dieter Felsenberg, Laurie K. McCauley, Felice O'Ryan, Ian R. Reid, Salvatore L. Ruggiero, Akira Taguchi, Sotirios Tetradis, Nelson B. Watts, Maria Luisa Brandi, Edmund Peters, Teresa Guise, Richard Eastell, Angela M. Cheung, Suzanne N. Morin, Basel Masri, Cyrus Cooper, Sarah L. Morgan, Barbara Obermayer-Pietsch, Bente L. Langdahl, Rana Al Dabagh, K. Shawn Davison, George K. Sándor, Robert G. Josse, Mohit Bhandari, Mohamed El Rabbany, Dominique D.

- Pierroz, Riad Sulimani, Deborah P. Saunders, Jacques P. Brown Juliet Compston on behalf of the International Task Force on Osteonecrosis of the Jaw. *Journal of Clinical Densitometry* Jan 2017
109. Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries Akira Taguchi, Masataka Shirak, Archie Morrison, Aliya A. Khan. *Osteoporosis and Sarcopenia* February 2017
110. Practice Five things to know about Atypical Femoral Fractures Aliya Aziz Khan MD, Stephanie Kaiser MD *CMAJ* 2017 April 10
111. Primary hyperparathyroidism: diagnosis and management in 2017 by Hamid Syed, Aliya Khan *POLISH ARCHIVES OF INTERNAL MEDICINE* 2017; 127 (6)
112. Tools for Enhancement and Quality Improvement of Peer Assessment and Clinical Care in Endocrinology and Metabolism by Aliya Khan, Anne Kenshole, Shereen Ezzat, Jeannette Goguen, Karen Gomez-Hernandez, Robert A. Hegele, Robyn Houlden, Tisha Joy, Erin Keely, Donald Killinger, André Lacroix, Sheila Laredo, Ally P.H. Prebtani, M. Z. Shrayyef, Chris Tran, Stan Van Uum, Rhoda Reardon, Antiope Papageorgiou, William Tays, and Merrill Edmonds *Journal of Clinical Densitometry* Sept 2017
113. A weekly 35,000 IU vitamin D supplementation improves bone turnover markers in vitamin D deficient Saudi adolescent females by Sulimani RA, Mohammed AG, Alshehri SN, Alfadda AA, Al-Othman A, Khan AA *Arch Osteoporos.* 2017 Sep 30;12(1):85. doi: 10.1007/s11657-017-0379-3.
114. Corrigendum to "Evaluation and Management of Skeletal Health in Celiac Disease: Position Statement" by Mona Fouda, Aliya Khan, Muhammad Sultan and David Armstrong Jan 2017
115. Phosphaturic Mesenchymal Tumour (PMT) of the Ethmoid Sinus Confirmed with Chromogenic In-Situ Hybridization for FGF23 JCD 2015 by Waleed Hashem, Waleed Khan, Andrew Folpe and Aliya Khan
116. Hyperparathyroidism by John P Bilezikian, Leonardo Bandeira, Aliya Khan, Natalie E Cusano *Lancet* Sept 2017
117. Score Distributions of the Balance Outcome Measure for Elder Rehabilitation (BOOMER) in Community-Dwelling Older Adults With Vertebral Fracture. by Brown ZM, Gibbs JC, Adachi JD, Ashe MC, Hill KD, Kendler DL, Khan A, Papaioannou A, Prasad S, Wark JD, Giangregorio LM *Journal of Geriatric Physical Therapy* 2017 Nov 28
118. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab by Felicia Cosman, Daria B. Crittenden, Serge Ferrari, Aliya Khan, Nancy E. Lane, Kurt Lippuner, Toshio Matsumoto, Cassandra E. Milmont, Cesar Libanati and Andreas Grauer *Journal of Bone Mineral Research* March 2018
119. Build better bones with exercise (B3E pilot trial): results of a feasibility study of a multicenter randomized controlled trial of 12 months of home exercise in older women with vertebral fracture *Osteoporosis International* L.M. Giangregorio, J.C. Gibbs, J.A. Templeton, J.D. Adachi, M.C. Ashe, R.R. Bleakney, A.M. Cheung, K.D. Hill, D.L. Kendler, A. A. Khan, S. Kim, C. McArthur, N. Mittmann, A. Papaioannou, S. Prasad, S.C. Scherer, L. Thabane & J.D. Wark November 2018, Volume 29, Issue 11, pp 2545–2556
120. Medical Hypoparathyroidism. Siraj N, Hakami Y, Khan A *Endocrinology and Metabolism Clinics of North America.* 2018 Dec;47(4):797-808. doi: 10.1016/j.ecl.2018.07.006. Epub 2018 Oct 11.
121. Management of Endocrine Disease: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. Khan AA, Clarke B, Rejnmark L, Brandi ML *European Journal of Endocrinology* 2019 Feb 1;180(2):R37-R44. doi: 10.1530/EJE-18-0541.
122. Standards of Care for Hypoparathyroidism in Adults. Khan AA, Koch C, Van Uum SHM, Baillargeon JP, Bollerslev J, Brandi ML, Marcocci C, Rejnmark L, Rizzoli R, Shrayyef MZ, Thakker RV, Yildiz BO, Clarke B. *European Journal of Endocrinology* (2019) 180, P1–P23
123. Exploring the association between number, severity location of fracture, and occiput-to-wall distance. Ziebart C, Adachi JD, Ashe MC, Bleakney RR, Cheung AM, Gibbs JC, Hill KD, Kendler DL, Khan AA, Kim S, McArthur C, Mittmann N, Papaioannou A, Prasad S, Scherer SC, Thabane L, Wark JD, Giangregorio LM. *Archives of Osteoporosis* (2019) 14: 27.

124. Hypophosphatasia: Canadian Update on diagnosis and management. AA Khan, R. Josse, P. Kannu, J. Villeneuve, T. Paul, S. Van Uum, C.R. Greenberg *Osteoporosis International* March 2019 epub
125. Are osteoporotic vertebral fractures or forward head posture associated with performance-based measures of balance and mobility? Ziebart, C., Gibbs, J. C., McArthur, C., Papaioannou, A., Mittmann, N., Laprade, Khan AA, & Thabane, L. *Archives of Osteoporosis*, (2019) 14(1), 67.
126. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Amaral Mendes R, Beadle BM, Beier Jensen S, Saunders DP. *Journal of Clinical Oncology*. 2019 Jul 22. DOI: 10.1200/JCO.19.01186. [Epub ahead of print]
127. Hypoparathyroidism by Yasser Hakami and Aliya Khan *Front Horm Res*, 51, 109-126, 2019 Karger publications Editor Maria Luisa Brandi
128. Gibbs JC, McArthur C, Wark JD, Thabane L, Scherer SC, Prasad S, Papaioannou A, Mittmann N, Laprade J, Kim S, Khan A, Kendler DL, Hill KD, Cheung AM, Bleakney R, Ashe MC, Adachi JD, Giangregorio LM. The effects of home exercise in older women with vertebral fractures: A pilot randomized controlled trial. *Phys Ther*. 2020 Jan 3. pii: pzz188. doi: 10.1093/ptj/pzz188. [Epub ahead of print]
129. Changes in Treatment needs of hypoparathyroidism during pregnancy and lactation : a case series - *Clinical Endocrinology* by Etki A. R. Hartogsohn Aliya A. Khan, Underbjerg Kjærulf Tanja Sikjaer Sharjil Hussain, Lars Rejnmark, April 2020
130. Khan AA, Rejnmark L, Schwarz PE, Vokes TJ, Clarke BL, Rubin MR, Hofbauer LC, Erikson E, Palermo A, Pagotto U, Marcocci C, Ahmed I, Mourya S, Markova D, Karpf DB. SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism. *J Endocr Soc*. 2020 May 8;4(Suppl 1):SAT-LB72. doi: 10.1210/jendso/bvaa046.2209. PMID: PMC7208407.
131. Baseline Characteristics from the Observational PARADIGM Registry of Patients with Chronic Hypoparathyroidism *Journal of the Endocrine Society*, Volume 4, Issue Supplement_1, April-May 2020, SAT-399, <https://doi.org/10.1210/jendso/bvaa046.591> Published: 08 May 2020 Bart L Clarke, MD; Lars Rejnmark, PhD, DMSc; Steven W Ing, MD, MSCE; Maria Luisa Brandi, MD, PhD; Sigridur Björnsdóttir, MD, PhD; Lorenz C Hofbauer, MD; Pascal Houillier, MD, PhD; Aliya A Khan, MD; Michael A Levine, MD; Michael Mannstadt, MD; Dolores M Shoback, MD; Tamara J Vokes, MD; Pinggao Zhang.
132. Aliya Aziz Khan, Hajar Abu Alrob, Iman M'Hiri, Hosay Said, Sharjil Hussain, Ismail Hweija, Salman Iqbal, Shawn K Davison, Romanovschi Mihai, Hafsa Haneef, Mona Qutub, Heather Zariffah, SUN-377 Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Real World, Prospective Observational Study, *Journal of the Endocrine Society*, Volume 4, Issue Supplement_1, April-May 2020, SUN-377, <https://doi.org/10.1210/jendso/bvaa046.1431>
133. Osteoporosis treatment rate following hip fracture in a community hospital. Aliya A. Khan, Hajar AbuAlrob, Farhan Tariq, Madiha Tauqir, Paul Zalzal, Iman M'Hiri, Moin Khan, Mark Ginty, Brad Weening. *Archives of osteoporosis* Jan 2021
134. Diagnosis of Osteoporosis: Clinical and Densitometric Analysis *CARJ* July 2020 Aliya A. Khan, MD, FRCPC, FACP, FACE, CCD, Hema Nalini Choudur, MBBS, FRCPC, and Brian Lentle, MB, MD, DSc(hc), FRCPC, FRCR, FACR, CCD
135. Khan AA, AbuAlrob H, Punthakee Z, Shrayyef M, Werfalli RE, Kassem HA, Braga M, Millar A, Hussain S, Iqbal S, Khan T, Paul T, Van Uum S, Young JEM. Canadian national hypoparathyroidism registry: an overview of hypoparathyroidism in Canada. *Endocrine*. 2021 May;72(2):553-561. doi: 10.1007/s12020-021-02629-w. Epub 2021 Mar 2. PMID: 33655415.
136. Dandurand K, Ali DS, Khan AA. Hypercalcemia in Pregnancy. *Endocrinol Metab Clin North Am*. 2021 Dec;50(4):753-768. doi: 10.1016/j.ecl.2021.07.009. PMID: 34774246.
137. Ali, D.S.; Dandurand, K.; Khan, A.A. Hypoparathyroidism in Pregnancy and Lactation: Current Approach to Diagnosis and Management. *J. Clin. Med*. 2021, 10, 1378.

138. Dandurand, K.; Ali, D.S.; Khan, A.A. Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management. *Journal of Clinical Medicine*. 2021; 10(8):1604. <https://doi.org/10.3390/jcm10081604> *J. Clin. Med.* 2021, 10, 1604.
139. Ali, D.S., Dandurand, K., Khan, A.A. 2021. Primary Hyperparathyroidism in Pregnancy: Literature Review of the Diagnosis and Management. *Journal of Clinical Medicine* 10, 2956.. doi:10.3390/jcm10132956 *Journal of Clinical Medicine*. 2021; 10(7):1378. <https://doi.org/10.3390/jcm10071378>
140. Khan A, Rejnmark L, Rubin M, et al. PaTH Forward: A randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism. *J Clin Endocrinol Metab*. Published online 2021.
141. Special Issue "Primary Hyperparathyroidism and Hypoparathyroidism: Diagnosis and Management" JCM Sept 2021 Guest Editor Prof Aliya Khan
142. The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics by Neil Gittoes, Lars Rejnmark, Steven W. Ing, Maria Luisa Brandi, Sigridur Björnsdóttir, Stefanie Hahner, Lorenz C. Hofbauer, Pascal Houillier, Aliya A. Khan, Michael A. Levine, Michael Mannstadt, Dolores M. Shoback, Tamara J. Vokes, Pinggao Zhang, Claudio Marelli, John Germak & Bart L. Clarke *BMC Endocrine Disorders* volume 21, Article number: 232 (2021)
143. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS – JCEM Jan 2022 Athanasios D. Anastasilakis,^{1,*} Jessica Pepe,^{2,*} Nicola Napoli,^{3,*} Andrea Palermo,³ Christos Magopoulos,⁴ Aliya A. Khan,⁵ M. Carola Zillikens,⁶ and Jean-Jacques Body⁷
144. Bell, A., Kendler, D.L., Khan, A.A. et al. A retrospective observational study of osteoporosis management after a fragility fracture in primary care. *Arch Osteoporos* 17, 75 (2022). <https://doi.org/10.1007/s11657-022-01110-z>
145. Guideline No. 422g: Menopause and Osteoporosis Khan, Aliya A. Alrob, Hajar AbuAli, Dalal S. Dandurand, KarelWolfman, WendyFortier, Michel et al. *Journal of Obstetrics and Gynecology Canada*, Volume 44, Issue 5, 527 - 536.e5
146. Understanding Osteoporosis Management from the Perspective of People at Risk of Fracturing Dovepress July 2022 Christina Ziebart¹, Joy MacDermid^{2,3}, Rochelle Furtado¹, Mike Szekeres³, Nina Suh³, Aliya Khan⁴
147. Yao L, Guyatt G, Ye Z, Bilezikian JP, Brandi ML, Clarke BL, Mannstadt M, Khan AA. Methodology for the Guidelines on Evaluation and Management of Hypoparathyroidism and Primary Hyperparathyroidism. *J Bone Miner Res*. 2022 Nov;37(11):2404-2410. doi: 10.1002/jbmr.4687. Epub 2022 Oct 17. PMID: 36053800.
148. Van Uum S, Shrayyef M, M'Hiri I, Dandurand K, Ali DS, Bilezikian JP, Collins MT, Mannstadt M, Rubin MR, Siggelkow H, Tabacco G, Tay YD, Vokes T, Winer KK, Yao L, Guyatt G, Rejnmark L, Khan AA. Initial Assessment and Monitoring of Patients with Chronic Hypoparathyroidism: A Systematic Current Practice Survey. *J Bone Miner Res*. 2022 Dec;37(12):2630-2641. doi: 10.1002/jbmr.4698. Epub 2022 Nov 14. PMID: 36066096.
149. Yao L, Li J, Li M, Lin C, Hui X, Tamilselvan D, Kandi M, Sreekanta A, Makhdami N, Ali DS, Dandurand K, Yang K, Bilezikian JP, Brandi ML, Clarke BL, Mannstadt M, Rejnmark L, Khan AA, Guyatt G. Parathyroid Hormone Therapy for Managing Chronic Hypoparathyroidism: A Systematic Review and Meta-Analysis. *J Bone Miner Res*. 2022 Dec;37(12):2654-2662. doi: 10.1002/jbmr.4676. Epub 2022 Nov 16. PMID: 36385517.
150. Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Gittoes NJ, Pasieka JL, Rejnmark L, Shoback DM, Potts JT, Guyatt GH, Mannstadt M. Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop. *J Bone Miner Res*. 2022 Dec;37(12):2568-2585. doi: 10.1002/jbmr.4691. Epub 2022 Nov 14. PMID: 36054621.
151. Khan AA, Guyatt G, Ali DS, Bilezikian JP, Collins MT, Dandurand K, Mannstadt M, Murphy D, M'Hiri I, Rubin MR, Sanders R, Shrayyef M, Siggelkow H, Tabacco G, Tay YD, Van Uum S, Vokes T, Winer KK, Yao L, Rejnmark L. Management of Hypoparathyroidism. *J Bone Miner Res*. 2022 Dec;37(12):2663-2677. doi: 10.1002/jbmr.4716. Epub 2022 Oct 31. PMID: 36161671.
152. Editorial -The 2nd International Workshop on the Evaluation and Management of Hypoparathyroidism JBMR 2022 by Aliya A Khan¹ John P Bilezikian,² Maria Luisa Brandi³ Bart L Clarke,⁴ John T Potts,⁵ Michael Mannstadt

153. Editorial - The Fifth International Workshop on the Evaluation and Management of Primary Hyperparathyroidism JBMR 2022 by John P Bilezikian, ¹ [Aliya A Khan](#), ² Bart L Clarke, ³ Michael Mannstadt, ⁴ John T Potts, ⁴ Maria Luisa Brandi ⁵
154. Bilezikian JP, [Khan AA](#), Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S, Perrier N, Sitges-Serra A, Thakker RV, Guyatt G, Mannstadt M, Potts JT, Clarke BL, Brandi ML; International Workshop on Primary Hyperparathyroidism. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. *J Bone Miner Res.* 2022 Nov;37(11):2293-2314. doi: 10.1002/jbmr.4677. Epub 2022 Oct 17. PMID: 36245251.
155. Ye Z, Silverberg SJ, Sreekanta A, Tong K, Wang Y, Chang Y, Zhang M, Guyatt G, Tangamornsuksun W, Zhang Y, Manja V, Bakaa L, Couban RJ, Brandi ML, Clarke B, [Khan AA](#), Mannstadt M, Bilezikian JP. The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Bone Miner Res.* 2022 Nov;37(11):2351-2372. doi: 10.1002/jbmr.4685. Epub 2022 Oct 17. PMID: 36053960.
156. Bilezikian, J.P., Silverberg, S.J., Bandeira, F., Cetani, F., Chandran, M., Cusano, N.E., Ebeling, P.R., Formenti, A.M., Frost, M., Gosnell, J., Lewiecki, E.M., Singer, F.R., Gittoes, N., [Khan, A.A.](#), Marcocci, C., Rejnmark, L., Ye, Z., Guyatt, G. and Potts, J.T. (2022), Management of Primary Hyperparathyroidism. *J Bone Miner Res*, 37: 2391-2403. <https://doi.org/10.1002/jbmr.4682>
157. Yao, L., Hui, X., Li, M., Li, J., Ahmed, M.M., Lin, C., Kandi, M., Sreekanta, A., Makhdami, N., Tamilselvan, D., Ali, D.S., Dandurand, K., Yang, K., Bilezikian, J.P., Brandi, M.L., Clarke, B.L., Mannstadt, M., Rejnmark, L., [Khan, A.A.](#) and Guyatt, G. (2022), Complications, Symptoms, Pre-surgical Predictors in Patients with Chronic Hypoparathyroidism: A Systematic Review. *J Bone Miner Res.* Accepted Author Manuscript. <https://doi.org/10.1002/jbmr.4673>
158. [Khan AA](#), Brandi ML, Rush ET, Ali DS, Al-Alwani H, Almonaei K, Alsarraf F, Bacrot S, Dahir KM, Dandurand K, Deal C, Ferrari SL, Giusti F, Guyatt G, Hatcher E, Ing SW, Javaid MK, Khan S, Kocijan R, Linglart A, M'Hiri I, Marini F, Nunes ME, Rockman-Greenberg C, Roux C, Seefried L, Simmons JH, Starling SR, Ward LM, Yao L, Brignardello-Petersen R, Lewiecki EM. Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. *Osteoporos Int.* 2024 Mar;35(3):431-438. doi: 10.1007/s00198-023-06844-1. Epub 2023 Nov 20. Erratum in: *Osteoporos Int.* 2024 May;35(5):933-934. doi: 10.1007/s00198-024-07048-x. PMID: 37982857; PMCID: PMC10866785.
159. Brandi ML, [Khan AA](#), Rush ET, Ali DS, Al-Alwani H, Almonaei K, Alsarraf F, Bacrot S, Dahir KM, Dandurand K, Deal C, Ferrari SL, Giusti F, Guyatt G, Hatcher E, Ing SW, Javaid MK, Khan S, Kocijan R, Lewiecki EM, Linglart A, M'Hiri I, Marini F, Nunes ME, Rockman-Greenberg C, Seefried L, Simmons JH, Starling SR, Ward LM, Yao L, Brignardello-Petersen R, Roux C. The challenge of hypophosphatasia diagnosis in adults: results from the HPP International Working Group Literature Surveillance. *Osteoporos Int.* 2024 Mar;35(3):439-449. doi: 10.1007/s00198-023-06859-8. Epub 2023 Nov 20. Erratum in: *Osteoporos Int.* 2024 May;35(5):933-934. doi: 10.1007/s00198-024-07048-x. PMID: 37982856.
160. Rush E, Brandi ML, [Khan A](#), Ali DS, Al-Alwani H, Almonaei K, Alsarraf F, Bacrot S, Dahir KM, Dandurand K, Deal C, Ferrari SL, Giusti F, Guyatt G, Hatcher E, Ing SW, Javaid MK, Khan S, Kocijan R, Lewiecki EM, Linglart A, M'Hiri I, Marini F, Nunes ME, Rockman-Greenberg C, Roux C, Seefried L, Starling SR, Ward L, Yao L, Brignardello-Petersen R, Simmons JH. Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group. *Osteoporos Int.* 2024 Jan;35(1):1-10. doi: 10.1007/s00198-023-06843-2. Epub 2023 Nov 20. PMID: 37982855; PMCID: PMC10786745.
161. [Khan AA](#), AbuAlrob H, M'Hiri I, Ali DS, Dandurand K, Said H, Alkasssem H, Hakami Y, Hweija I, Iqbal S, Romanovschi M, Mehmood S, Zariffah H, Guyatt G, Ibrahim Q, Brignardello-Petersen R, Syed HI. Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study. *Endocrine.* 2023 Jun;80(3):647-657. doi: 10.1007/s12020-022-03230-5. Epub 2023 Apr 25. PMID: 37186270; PMCID: PMC10199867.
162. [Khan AA](#), Rubin MR, Schwarz P, Vokes T, Shoback DM, Gagnon C, Palermo A, Marcocci C, Clarke BL, Abbott LG, Hofbauer LC, Kohlmeier L, Pihl S, An X, Eng WF, Smith AR, Ukena J, Sibley CT, Shu AD, Rejnmark L. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. *J Bone Miner Res.* 2023 Jan;38(1):14-25. doi: 10.1002/jbmr.4726. Epub 2022 Nov 12. PMID: 36271471; PMCID: PMC10099823.

163. Khan AA, AbuAlrob H, Al-Alwani H, Ali DS, Almonaei K, Alsarraf F, Bogoch E, Dandurand K, Gazendam A, Juby AG, Mansoor W, Marr S, Morgante E, Myslik F, Schemitsch E, Schneider P, Thain J, Papaioannou A, Zalzal P. Post hip fracture orthogeriatric care-a Canadian position paper addressing challenges in care and strategies to meet quality indicators. *Osteoporos Int.* 2023 Jun;34(6):1011-1035. doi: 10.1007/s00198-022-06640-3. Epub 2023 Apr 4. PMID: 37014390; PMCID: PMC10202990. Chosen as "article of the month by Bone Health Alliance Foundation"
164. Jan de Beur SM, Minisola S, Xia WB, Abrahamsen B, Body JJ, Brandi ML, Clifton-Bligh R, Collins M, Florenzano P, Houillier P, Imanishi Y, Imel EA, Khan AA, Zillikens MC, Fukumoto S. Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. *J Intern Med.* 2023 Mar;293(3):309-328. doi: 10.1111/joim.13593. Epub 2022 Dec 13. PMID: 36511653; PMCID: PMC10108006.
165. Ing SW, Finkelman RD, He P, Khan AA, Mannstadt M, Rejnmark L, Song I, Takács I, Wu Y. A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for Hypoparathyroidism. *JBMR Plus.* 2023 May 31;7(7):e10758. doi: 10.1002/jbm4.10758. PMID: 37457880; PMCID: PMC10339078.
166. Lane NE, Betah D, Deignan C, Oates M, Wang Z, Timoshanko J, Khan AA, Binkley N. Effect of Romosozumab Treatment in Postmenopausal Women With Osteoporosis and Knee Osteoarthritis: Results From a Substudy of a Phase 3 Clinical Trial. *ACR Open Rheumatol.* 2024 Jan;6(1):43-51. doi: 10.1002/acr2.11619. Epub 2023 Nov 20. PMID: 37985218; PMCID: PMC10789302.
167. Hypophosphatasia: Presentation and Response to Asfotase Alfa , *Osteoporosis International November 2023* by Farah Alsarraf¹, Dalal S. Ali¹, Khulod Almonaei², Hatim Al-Alwani³, Aliya A. Khan¹, Maria Luisa Brandi^{4,5}
168. Case Report: A Novel Heterozygous Mutation c.1627G>T (p.Gly543Cys) in the SLC34A1 Gene in a Male Patient with Recurrent Nephrolithiasis and Early Onset Osteopenia: A Case Report Francesca Giusti^{1,2,†}, Francesca Marini^{3,†}, Hatim Al-alwani⁴, Elena Marasco⁵, Paolo Garagnani^{5,6,7}, Aliya A. Khan⁴ and Maria Luisa Brandi^{1,3,8} *Int. J. Mol. Sci.* 2023, 24, 17289
169. rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes Maria Luisa Brandi,¹ Tamara Vokes,² Natasha M. Appelman-Dijkstra,³ Olulade Ayodele,^{4,*} Brigitte Decallonne,⁵ Renate de Jongh,⁶ Manuel Díaz-Curiel,⁷ William Fraser,⁸ Richard D. Finkelman,⁹ Ansgar Heck,¹⁰ Steven W. Ing,¹¹ Peter Kamenicky,¹² Aliya A. Khan,¹³ Christopher S. Kovacs,¹⁴ Bruno Lapauw,¹⁵ Graham Leese,¹⁶ Giovanna Mantovani,^{17,18} Guillermo Martínez Díaz-Guerra,¹⁹ Laura Masi,²⁰ Miguel Melo,²¹ Andrea Palermo,^{22,23} Narendra L. Reddy,²⁴ Lars Rejnmark,²⁵ Elena Tokareva,⁴ Marie-Christine Vantuyghem,²⁶ Suwei Wang,⁴ Mark Warren,²⁷ and Brian Yan⁴
170. Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update Suzanne N. Morin MD MSc, Sidney Feldman MD, Larry Funnell, Lora Giangregorio PhD, Sandra Kim MD, Heather McDonald-Blumer MD, Nancy Santesso PhD, Rowena Ridout MD, Wendy Ward PhD, Maureen C. Ashe PhD, Zahra Bardai MD, Joan Bartley, Neil Binkley MD, Steven Burrell MD, Debra Butt MD, Suzanne M. Cadarette PhD, Angela M. Cheung MD PhD, Phil Chilibeck PhD, Sheila Dunn MD, Jamie Falk PharmD, Heather Frame MD, William Gittings PhD, Kaleen Hayes PhD, Carol Holmes MD, George Ioannidis PhD, Susan B. Jaglal PhD, Robert Josse MD, Aliya A. Khan MD, Virginia McIntyre, Lynn Nash MD, Ahmed Negm MD PhD, Alexandra Papaioannou MD MSc, Matteo Ponzano PhD, Isabel B. Rodrigues PhD, Lehana Thabane PhD, Christine A. Thomas MBA, Lianne Tile MD, John D. Wark MBBS PhD; for the Osteoporosis Canada 2023 Guideline Update Group. Cite as: *CMAJ* 2023 October 10;195:E1333-48. doi: 10.1503/cmaj.221647
171. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial, *Advances in Therapy* Lars Rejnmark . Elvira O. Gosmanova . Aliya A. Khan . Noriko Makita . Yasuo Imanishi . Yasuhiro Takeuchi . Stuart Sprague . Dolores M. Shoback . Lynn Kohlmeier . Mishaela R. Rubin . Andrea Palermo . Peter Schwarz . Claudia Gagnon . Elena Tsourdi . Carol Zhao . Michael A. Makara . Michael S. Ominsky . Bryant Lai . Jenny Ukena . Christopher T. Sibley . Aimee D. Shu
172. Aliya A Khan, Lisa G Abbott, Intekhab Ahmed, Olulade Ayodele, Claudia Gagnon, Richard D Finkelman, Emese Mezosi, Lars Rejnmark, Istvan Takacs, Shaoming Yin, Steven W Ing, Open-label extension of a randomized

trial investigating safety and efficacy of rhPTH(1–84) in hypoparathyroidism, *JBMR Plus*, Volume 8, Issue 3, March 2024, ziad010, <https://doi.org/10.1093/jbmrpl/ziad010>

173. [Khan AA](#), [Slart RHJA](#), [Ali DS](#), [Bock O](#), [Carey JJ](#), [Camacho P](#), [Engelke K](#), [Erba PA](#), [Harvey NC](#), [Lems WF](#), [Morgan S](#), [Moseley KF](#), [O'Brien C](#), [Probyn L](#), [Punda M](#), [Richmond B](#), [Schousboe JT](#), [Shuhart C](#), [Ward KA](#), [Lewiecki EM](#); International Working Group on DXA Best Practices. Osteoporotic Fractures: Diagnosis, Evaluation, and Significance From the International Working Group on DXA Best Practices. *Mayo Clin Proc.* 2024 Jul;99(7):1127-1141. doi: 10.1016/j.mayocp.2024.01.011. PMID: 38960497.
174. [Portale AA](#), [Ward L](#), [Dahir K](#), [Florenzano P](#), [Ing SW](#), [Jan de Beur SM](#), [Martin RM](#), [Meza-Martinez AI](#), [Paloian N](#), [Ashraf A](#), [Dixon BP](#), [Khan A](#), [Langman C](#), [Chen A](#), [Wang C](#), [Roberts MS](#), [Tandon PK](#), [Bedrosian C](#), [Imel EA](#). Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study. *J Bone Miner Res.* 2024 Sep 26;39(10):1493-1502. doi: 10.1093/jbmr/zjae127. PMID: 39151033; PMCID: PMC11425691.
175. [Khan A](#), [Johnson B](#), [Nixon A](#), [Dent JE](#), [Li Z](#), [Yang E](#), [Williams A](#). Association between work productivity and characteristics of adults with X-linked hypophosphatemia: an analysis of the XLH disease monitoring program. *JBMR Plus.* 2024 Jul 29;8(11):ziae102. doi: 10.1093/jbmrpl/ziae102. PMID: 39464774; PMCID: PMC11512684.
176. [Hartogsohn EAR](#), [Khan AA](#), [Kjaersulf LU](#), [Sikjaer T](#), [Hussain S](#), [Rejnmark L](#). Changes in treatment needs of hypoparathyroidism during pregnancy and lactation: A case series. *Clin Endocrinol (Oxf).* 2020 Sep;93(3):261-268. doi: 10.1111/cen.14212. Epub 2020 May 19. PMID: 32350890.
177. [Alnajmi RAY](#), [Ali DS](#), [Khan AA](#). Diagnosis and Management of Atypical Femoral Fractures and Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis. *Endocrinol Metab Clin North Am.* 2024 Dec;53(4):607-618. doi: 10.1016/j.ecl.2024.08.007. PMID: 39448140.
178. [Ali DS](#), [Khan AA](#), [Brandi ML](#). Effective strategies for pregnancy and lactation-associated osteoporosis: teriparatide use in focus. *Endocrine.* 2024 Nov;86(2):459-469. doi: 10.1007/s12020-024-03946-6. Epub 2024 Jul 15. PMID: 39008200.
179. [Ali, D.S.](#), [Marini, F.](#), [Alsarraf, F.](#), [Alalwani, H.](#), [Alamri, A.](#), [Khan, A.A.](#), [Brandi, M.L.](#), 2023. Case Report: Calcium sensing receptor gene gain of function mutations: a case series and report of 2 novel mutations. *Frontiers in Endocrinology* 14.. <https://doi.org/10.3389/fendo.2023.1215036>
180. [Slart, R.H.J.A.](#), [Punda, M.](#), [Ali, D.S.](#), [Bazzocchi, A.](#), [Bock, O.](#), [Camacho, P.](#), [Carey, J.J.](#), [Colquhoun, A.](#), [Compston, J.](#), [Engelke, K.](#), [Erba, P.A.](#), [Harvey, N.C.](#), [Krueger, D.](#), [Lems, W.F.](#), [Lewiecki, E.M.](#), [Morgan, S.](#), [Moseley, K.F.](#), [O'Brien, C.](#), [Probyn, L.](#), [Rhee, Y.](#), [Richmond, B.](#), [Schousboe, J.T.](#), [Shuhart, C.](#), [Ward, K.A.](#), [Van Den Wyngaert, T.](#), [Zhang-Yin, J.](#), [Khan, A.A.](#), 2024. Updated practice guideline for dual-energy X-ray absorptiometry (DXA). *European Journal of Nuclear Medicine and Molecular Imaging*.. <https://doi.org/10.1007/s00259-024-06912-6>
181. [Alsarraf F](#), [Ali DS](#), [Almonaei K](#), [Al-Alwani H](#), [Khan AA](#), [Brandi ML](#). Hypophosphatasia: presentation and response to asfotase alfa. *Osteoporos Int.* 2024 Apr;35(4):717-725. doi: 10.1007/s00198-023-06943-z. Epub 2023 Nov 23. PMID: 37993691.

182. Association between work productivity and characteristics of adults with X-linked hypophosphatemia: an analysis of the XLH disease monitoring program

[Aliya Khan](#)¹, [Ben Johnson](#)², [Annabel Nixon](#)³, [Jennifer E Dent](#)³, [Zhiyi Li](#)⁴, [Erru Yang](#)⁵, [Angela Williams](#)² *JBMR plus* Nov 2024

183. Hypoparathyroidism: Similarities and differences between Western and Eastern countries Yuying Yang^{1,2} · Yanhua Deng^{1,2} · Lihao Sun^{1,2} · Lars Rejnmark³ · Ling Wang⁴ · Peter Pietschmann⁵ · Claus-Christian Glüer⁶ · Aliya Khan⁷ ·

184. Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult 2 Patients with X-Linked Hypophosphatemia 3 4 Authors: Dalal S. Ali*¹ , MD, MSc, Reza D. Mirza*² , MD, MSc, Farah Alsarraf^{1 5} , MD, Salma Hussein¹ , MD, Hajar Abu alrob² , PhD(c), Natasha M. Appelman-Dijkstra^{3 6} , MD, PhD, Signe Sparre Beck-Nielsen^{4,5} , MD, PhD, Martin Biosse-Duplan^{6 7} , DDS, PhD, Maria Luisa Brandi⁷ , MD, PhD, Thomas O. Carpenter⁸ , MD, Catherine Chaussain^{9 8} , DDS, PhD, Martine Cohen-Solal¹⁰ , MD, PhD, Rachel K. Crowley¹¹ , MD, PhD, Karel Dandurand^{12 9} , MD, Pablo Florenzano¹³ , MD, Seiji Fukumoto¹⁴ , MD, PhD, Claudia Gagnon^{15 10} , MD, Paul Goodyer¹⁶ , MD, Corinna Grasemann¹⁷ , MD, Erik A. Imel^{18 11} , MS, MD, Suzanne M. Jan de Beur¹⁹ , MD, Anna Lehman²⁰ , MD, E. Michael Lewiecki²¹ , MD, Emmett Morgante^{22 12} , B.Sc., Leanne M. Ward²³ , MD, Aliya A. Khan¹ , MD, Gordon Guyatt^{2,24,25 13} , MD JCEM Dec 25, 2024 online

185. Alnajmi, R., Ali, D. S., Alrob, H. A., & Khan, A. A. (2023). *Hypoparathyroidism Advances in Management*. In *Endocrinology* (pp. 1–22). Springer Nature Switzerland. https://doi.org/10.1007/978-3-030-19632-5_3-1

186.

Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients with X-Linked Hypophosphatemia, Dalal S Ali, MD, MSc, Reza D Mirza, MD, MSc, Farah Alsarraf, MD, Salma Hussein, MD, Hajar Abu alrob, PhD(c), Natasha M Appelman-Dijkstra, MD, PhD, Signe Sparre Beck-Nielsen, MD, PhD, Martin Biosse-Duplan, DDS, PhD, Maria Luisa Brandi, MD, PhD, Thomas O Carpenter, MD, Catherine Chaussain, DDS, PhD, Martine Cohen-Solal, MD, PhD, Rachel K Crowley, MD, PhD, Karel Dandurand, MD, Pablo Florenzano, MD, Seiji Fukumoto, MD, PhD, Claudia Gagnon, MD, Paul Goodyer, MD, Corinna Grasemann, MD, Erik A Imel, MS, MD, Suzanne M Jan de Beur, MD, Anna Lehman, MD, E Michael Lewiecki, MD, Emmett Morgante, BSc, Leanne M Ward, MD, Aliya A Khan, MD, Gordon Guyatt, MD *The Journal of Clinical Endocrinology & Metabolism*, 2024;December dgae890, <https://doi.org/10.1210/nem/dgae890>

187.

Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients with X-Linked Hypophosphatemia, Dalal S Ali, MD, MSc, Reza D Mirza, MD, MSc, Farah Alsarraf, MD, Salma Hussein, MD, Hajar Abu alrob, PhD(c), Natasha M Appelman-Dijkstra, MD, PhD, Signe Sparre Beck-Nielsen, MD, PhD, Martin Biosse-Duplan, DDS, PhD, Maria Luisa Brandi, MD, PhD, Thomas O Carpenter, MD, Catherine Chaussain, DDS, PhD, Martine Cohen-Solal, MD, PhD, Rachel K Crowley, MD, PhD, Karel Dandurand, MD, Pablo Florenzano, MD, Seiji Fukumoto, MD, PhD, Claudia Gagnon, MD, Paul Goodyer, MD, Corinna Grasemann, MD, Erik A Imel, MS, MD, Suzanne M Jan de Beur, MD, Anna Lehman, MD, E Michael Lewiecki,

MD, Emmett Morgante, BSc, Leanne M Ward, MD, Aliya A Khan, MD, Gordon Guyatt, MD *Journal of Clinical Endocrinology & Metabolism*, 2024; accepted.

187. *XLinked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline, JCEM in press – Khan et al*
188. *XLinked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline, JCEM, under review (Aug 2024) Dalal Ali, Khan et al*
189. *Methodology for the Guidelines on X-Linked Hypophosphatemia Diagnosis and Management in Children and Adults, Journal of Bone and Mineral Metabolism, Feb 5, 2025 Ali D and Khan AA shared 1st authors et al*
190. *Current Practices in Monitoring Children and Adults with X-Linked Hypophosphatemia: A Global Survey of Expert Experience, JCEM, under review (Aug 2024)*
191. *Antiresorptive Therapy to Reduce Fracture Risk and Effects on Dental Implant Outcomes in Patients with Osteoporosis: A Systematic Review and Consensus Statement, Endocrine Practice, under review (Nov 2024)*
192. Ali, D. S., A. A. Khan, and M. L. Brandi. "Effective Strategies for Pregnancy and Lactation-Associated Osteoporosis: Teriparatide Use in Focus." *Endocrine* 86, no. 2 (Nov 2024): 459-69. <https://dx.doi.org/10.1007/s12020-024-03946-6>.
193. Ali, D. S., F. Marini, F. Alsarraf, H. Alalwani, A. Alamri, A. A. Khan, and M. L. Brandi. "Case Report: Calcium Sensing Receptor Gene Gain of Function Mutations: A Case Series and Report of 2 Novel Mutations." *Front Endocrinol (Lausanne)* 14 (2023): 1215036. <https://dx.doi.org/10.3389/fendo.2023.1215036>.
194. *Skeletal Health Status Among Patients with Chronic Hypoparathyroidism: Results From The Canadian National Hypoparathyroidism Registry (CNHR). Osteoporosis International, (Jan 2025). Khan et al*
195. *Outcomes of Hypoparathyroidism in Pregnancy: An Observational Study from a Tertiary Canadian Center. The Journal of Obstetric and Gynecology Canada. Under review (Dec 2024)*
196. *Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial by Bart L. Clarke,¹ Aliya A. Khan,² Mishaela R. Rubin,³ Peter Schwarz,⁴ Tamara Vokes,⁵ Dolores M. Shoback,⁶ Claudia Gagnon,^{7,8} Andrea Palermo,^{9,10} Lisa G. Abbott,^{11,12} Lorenz C. Hofbauer,¹³ Lynn Kohlmeier,¹⁴ Filomena Cetani,¹⁵ Susanne Pihl,¹⁶ Xuebei An,¹⁷ Alden R. Smith,¹⁸ Bryant Lai,¹⁹ Jenny Ukena,¹⁹ Christopher T. Sibley,¹⁹ Aimee D. Shu,¹⁹ and Lars Rejnmark²⁰*
197. *Hypoparathyroidism- Diagnosis and Management -Nature Reviews Feb4, 2025 by Sarah Khan and Aliya A. Khan*
198. Ali DS, Khan AA, Tetradis S, Morrison A, Mirza RD, et al. "Antiresorptive Therapy to Reduce Fracture Risk and Effects on Dental Implant Outcomes in Patients with Osteoporosis: A Systematic Review and Consensus Statement." *Consensus Statement, Endocrine Practice, under review Feb 2025*

199. Alnajmi, R. A. Y., D. S. Ali, and A. A. Khan. "Diagnosis and Management of Atypical Femoral Fractures and Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis." *Endocrinol Metab Clin North Am* 53, no. 4 (Dec 2024): 607-18. <https://dx.doi.org/10.1016/j.ecl.2024.08.007>.
200. *Persistence and Recurrence of Primary Hyperparathyroidism* by Rasha A.Y. Alnajmi, Dalal S. Ali and Aliya A. Khan , *Best Practice and Research Clinical Endocrinology & Metabolism* March 2025

B. Books

1. Editor In Chief – “The Handbook of Parathyroid Diseases” Publisher Springer
New York
2012
2. *Tarascon Adult Endocrinology Pocketbook* by M. Laufgraben and G. Gopalakrishnan -
Publisher Jones & Bartlett Learning
Burlington, Maryland, USA
2013
Chapter "Hyperparathyroidism" - By Zohair Rahman and Aliya Khan
3. *The Textbook of Endocrine Surgery 3rd Edition*
Editors Orlo Clark and Quan Duh
Publisher Elsevier
2015
Chapter “Medical Management of Hyperparathyroidism” - By Aliya Khan, Zohair Rahman,
Jesse Pasternak and James Young.
4. *The Parathyroids 3rd Edition*
Editor Bilezikian JP
Publisher Elsevier
2014
Chapter “Hypoparathyroidism” - By Zohair Rahman and Aliya Khan
5. *The Parathyroids 3rd Edition*
Editor Bilezikian JP
Publisher Elsevier 2014
Chapter "Medical Management of primary hyperparathyroidism" by Claudio Marcocci and Aliya Khan
6. *Textbook of Hypoparathyroidism*
Editors Brandi ML and Brown EM
Publisher Springer 2014
Chapter "Role of Magnesium in parathyroid physiology" by Oren Steen and Aliya Khan
7. *Hypoparathyroidism e Book*
Projects in Knowledge
Chapter “ Diagnosis and evaluation “
8. *Textbook of Medical and Surgical Management of Parathyroid Disease*
Publisher Springer 2017
Chapter “ Hypercalcemia – Evidence based review on diagnosis and management“.
DOI 10.1007/978-3-319-26794-4_9

By Waleed Hashem, Christine Orr and Aliya Khan

9. Chapter 23: Magnesium Homeostasis
Aliya Aziz Khan, Asiya Sbayi, and Karl Peter Schlingmann
Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Ninth Edition.
Edited by John P. Bilezikian © 2019 American Society for Bone and Mineral Research.
Published 2019 by John Wiley & Sons, Inc.
10. Medical Hypoparathyroidism
Namrah Siraj MBBS, Yasser Hakami MD, and Aliya Khan MD
Hypoparathyroidism, An Issue of Endocrinology and Metabolism Clinics of North America,
Volume 47-4
Edited by Michael A Levine
Elsevier Published Date: 28th December 2018
11. Case Study in Hypoparathyroidism: Management of a Pregnant Patient With Pre-existing Hypoparathyroidism
Contributing Editor: Aliya Khan, MD, FRCPC, FACP, FACE
Medical Writer: Ursula Jorch, MSc, Med
Co-provided by Endocrine Society and Projects In Knowledge. These independent CME/CE activities are supported
by an educational grant from Shire 2018
12. Hypoparathyroidism in Pregnancy
Alalawi Y, M'Hiri I, Abu Alrob H, Khan AA
Clinical Casebook on Hypoparathyroidism
Publisher Springer, 2019 , Editor Cusano N
13. American College of Physicians – Hypercalcemia online module, 2019
14. McMaster Textbook of Internal Medicine “Hypoparathyroidism“
Alalawi Y, Abu Alrob H, M'Hiri I, Zariffah H, Khan AA
Publisher McMaster University, 2019
15. Volume Editor Bone metabolism, parathyroid gland, calcitropic hormones Publisher Springer 2020
16. Creasy & Resnik's Maternal-Fetal Medicine 9e, Chapter 62: Other Endocrine Disorders of pregnancy by Erin Keely
and Aliya Khan 2021
17. Textbook of Medical and Surgical Management of Parathyroid Disease
Publisher Springer 2024
Chapter “ Hypercalcemia – Evidence based review on diagnosis and management “
By Sarah Alajmi, Ali Alghar, Sultan Alharbi, Dalal S Ali and Aliya A. Khan MD, FRCPC, FACP, FACE
18. ASBMR Primer 2024 - Hypoparathyroidism : Diagnosis, Evaluation and Management
By Aliya A. Khan MD, Dalal Ali MD, Lars Rejnmark MD
19. Alnajmi, R., Ali, D. S., Alrob, H. A., & Khan, A. A. (2023). Hypoparathyroidism Advances in Management. In
Endocrinology (pp. 1–22). Springer Nature Switzerland. https://doi.org/10.1007/978-3-030-19632-5_3-1
20. Khan S, Ali DS, Young JEM, Rodríguez-Gutiérrez R, Kokot F, Franek E, Płaczkiwicz-Jankowska E, Khan AA. Primary Hyperparathyroidism. McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. [website_address] Accessed [access_date].

21.

C. Not Peer Reviewed:

1. "A Current Approach to Osteoporosis"
By: A. A. Khan
Canadian Journal of Diagnosis July 1994
2. "Osteoporosis Management"
By: A. A. Khan
The Spine Line. October 1994
3. "Drug Treatment of Osteoporosis"
By: A. A. Khan
The Spine Line, March 1995
4. "Osteoporosis and Vitamin D"
By: A. A. Khan
Canadian Journal of Diagnosis June 1995
5. "Osteoporosis: Patient Information"
By: A. A. Khan
Canadian Journal of Diagnosis March 1996
6. "Advances in Osteoporosis Treatment"
By: A. A. Khan
The Spine Line, April 1996
7. "Calcium and Vitamin D"
By: A. A. Khan
W.A.O. News, September 1996
(Chapter of Osteoporosis Society of Canada)
8. "Clinical Research in Osteoporosis"
By: A. A. Khan
The Spine Line, October 1996
9. "Osteoporosis Questions and Answers"
By: A. A. Khan
W.A.O. News, Spring 1997 (Chapter of Osteoporosis Society of Canada)
10. "Advances in Osteoporosis Research"
By: A. A. Khan
The Spine Line, October 199
11. "Vertebral Fractures in Osteoporosis"
By: A. A. Khan
Canadian Journal of Diagnosis November 1997
12. "Boning up on Osteoporosis - Advances in current Research"
By: A. A. Khan
Canadian Journal of Diagnosis December 1997
13. "Update on Osteoporosis Therapy"

By: A. A. Khan
The Spine Line, fall 1998

14. "Osteoporosis Research: Focus on Prevention"
By: A. A. Khan
Canadian Journal of Diagnosis March 1999
15. "Canadian ISCD Certification"
By: A. A. Khan
SCAN, official newsletter of the International Society for Clinical Densitometry, fall 1999
16. "Osteopenia in African American Pre-menopausal Women"
By: A. A. Khan
SCAN, official newsletter of the International Society for Clinical Densitometry, winter 1999
17. "Canada wide Osteoporosis Event"
By: A. A. Khan
SCAN, official newsletter of the International Society for Clinical Densitometry, winter 1999
18. "Advances in Osteoporosis Management"
By: A. A. Khan
The Spine Line, April 2000
19. "Understanding Primary Hyperparathyroidism"
By: A. A. Khan
Canadian Journal of Diagnosis June 2000
20. *International Bone Densitometry Certification*
SCAN, official newsletter of the International Society for Clinical Densitometry, winter 2000
21. *Treatment of Osteoporosis Management of Osteoporosis in Canada*
Advanced Healthcare Strategies, September 2000
22. *International ISCD Initiatives*
SCAN, official newsletter of the International Society for Clinical Densitometry, summer 2001
23. *Canadian Panel Update*
SCAN, official newsletter of the International Society for Clinical Densitometry, winter 2001
24. *Healthy Women*, a publication of the Society of Obstetricians and Gynaecologists of Canada, *Boning up on bisphosphonates*, Supplement 2002, pages 1-4.
25. *HRT – What's the Controversy* *Canadian Journal of Diagnosis* September 2002, pages 69-77.
26. *Colloquium: Current Practice in the Diagnosis and Treatment of Andropause*, *Medical Post* 2003
27. *Canadian Panel Update*
By: A.A. Khan
SCAN, official newsletter of the International Society for Clinical Densitometry, Vol IX, Quarter 3, 2003
28. *Letter to the Editor Response Osteoporosis Silent Epidemic* *Canadian Family Physician* July 2003, Vol 49, 865-866.
29. *Setting a New Standard Early Detection of Osteoporosis*

Khan AA, and the ISCD Canadian Panel
The Canadian Journal of Diagnosis July 2003:60-64

30. Canadian Panel Update
SCAN, official newsletter of the International Society for Clinical Densitometry, Vol X, Quarter 4, 2003
31. Certification Exam Committee Update
SCAN, official newsletter of the International Society for Clinical Densitometry, Vol X, Quarter 1, 2004.
32. *The Foundation for Medical Practice Education, Practice Based Learning Programs (PBLP), McMaster University – Spring 2004 Issue*
Key Points from the Canadian Standards for Central DXA in Premenopausal Women, Men, and Children
33. “International Society of Clinical Densitometry Certification Committee Report”
Scan, Volume 10, No. 1, 2004 by A.A. Khan
34. “Osteoporosis in Men” by Nadine Majid and Aliya Khan
Diagnosis, October, 2004.
35. *ISCD Certification Report 2004, Year-End*
36. “Anabolic Agents: New Approaches to Osteoporosis Treatment”
By: A.A Khan
The Canadian Journal of Diagnosis, Volume 22, June 2005, p 65-66
37. “Defining Bone-Fracture Prevalence, Risk Factors and Optimal Therapy”
Physician Perspective, March 2005 by A A Khan
38. “Screening men for osteoporosis” Answered by: AA Khan
The Canadian Journal of Diagnosis, Volume 22, June 2005
39. “Osteoporosis Part 1, Exciting new options for advanced disease”
By AA Khan, Moin Khan
Parkhurst Exchange, Volume 13, Number 7, July 2005, p 92-98
40. “Osteoporosis Part 2, Investigating low bone density in men and premenopausal women”
By Faizan Amin, AA Khan
Parkhurst Exchange, Volume 13, Number 8, August 2005, p100-105
41. “International Society of Clinical Densitometry Certification Committee Report”
Scan, Volume 10, 2005 By A.A. Khan
42. “Vitamin D Deficiency 2006” by Moin Khan and Aliya Khan
The Canadian Journal of Diagnosis, Vol. 23, no.1, 91-94, January 2006
43. “Hypercalcemia Today” by Kashif Yousuf and Aliya Khan
The Canadian Journal of Diagnosis, pp 75-80, February 2006
44. *SCAN – official newsletter of the ISCD, Volume 12, Quarter 2, 2006*
“ISCD Certification Council Report”
45. “Wait and see approach with osteopenia?” Experts on Call, *The Canadian Journal of Diagnosis* Volume 23, Number7, July 2006-07-19

46. SCAN – official newsletter of the ISCD, Volume 12, Quarter 3, 2006 “Certification Council Update”
47. “Medically Managing Primary Hyperparathyroidism”
By Waseema Hoosainny; and Aliya Khan
The Canadian Journal of Diagnosis, Volume 24, July 2007, p 43
48. “Premenopausal Osteoporosis,” By: Aliya Khan, The Canadian Journal of Diagnosis, July 2008
49. “Renal Osteodystrophy,” By: Aliya Khan, The Canadian Journal of Diagnosis, Vol 25, No 4, April 2008
50. “Approach to the Patient with Hypercalcemia: Diagnostic Principles”, By: Rachel Shour, Aliya Khan, Canadian Journal of
Diagnosis, April 2009, pg 55-58
51. “Primary Hyperparathyroidism,” By: Shelley Pallan and Aliya Khan, The Canadian Journal of Diagnosis, May 2009, pg 51-53
52. “Thiazolidinediones and Bone Disease,” By: Mohammed Rahman, Aliya Khan and Terri Paul, The Canadian Journal of
Diagnosis, Nov-Dec 2009, pg 51-52
53. “Nonresponders to Bisphosphonate Therapy”, By: Aakash Bhargava, Mohamed El-Rabbany, Aliya Khan, The Canadian
Journal of Diagnosis, Vol 27, No 6, June 2010
54. “An Update on Osteoporosis”, By Aliya Khan, The Canadian Journal of Diagnosis, Vol 27, No 7, July 2010
55. “Hypoparathyroidism”, By Jeremy Fong, Aliya Khan, The Canadian Journal of Diagnosis, Vol 27, No 10, October 2010
56. Calcium supplements and risk of heart disease Rapid Response by Aliya Khan and the Rapid
Response Team for Osteoporosis Canada Jan 23, 2013
57. “Epidemiology of osteoporotic fractures” Canadian Orthopedic Association Bulletin, Winter 2014
58. Atypical Femoral Fractures – Medical Post February 2017
59. Increased risk of vertebral fracture after stopping denosumab By Aliya Khan, Sandra Kim, Rowena Ridout, and
Lianne Tile Sept 2018 Rapid Response
60. Frequency of BMD assessments – when to repeat the BMD (Bone Mineral Density) Study by Aliya Khan, Sandra
Kim , Rowena Ridout and Lianne Tile June 2019 Rapid Response Osteoporosis Canada
61. Vitamin D and potential impact on the severity of COVID-19 Rapid Response from Osteoporosis Canada By Aliya Khan, Rowena Ridout,
Heather Frame, Claudia Gagnon, Lianne Tile, Wendy Ward, David Hanley, Sandra Kim May 2020 Rapid Response for Osteoporosis
Canada
62. Celiac Disease and Bone Health Rapid Response by Aliya Khan, Heather Frame, Claudia Gagnon, Rowena Ridout ,
Lianne Tile, Wendy Ward, Sandra Kim Rapid Response for Osteoporosis Canada
63. COVID-19 VACCINATION AND OSTEOPOROSIS DRUG THERAPY March 23, 2021 by Dr. Aliya Khan, Dr.
Heather Frame, Dr. Claudia Gagnon, Dr. Rowena Ridout, Dr. Lianne Tile and Dr. Sandra Kim
Recommendations from Osteoporosis Canada Rapid Response Team

CONSULTING

2008 – 2009: Member of the Data Safety Monitoring Board evaluating prednisolone in osteoarthritis (combinatoRx)
Current: Advisory Board Member; Alexion, Amgen, Ascendis, Takeda, Ultragenyx
2019 – Member of CADTH evaluating Burosumab

CURRENT TEACHING INVOLVEMENT:

McMaster University

- a. Endocrine section Unit 3 - preceptor
- b. Preceptor - elective - Metabolic Bone Disease
- c. Preceptor – Geriatric rotation
- d. MF 2 lecture for endocrine subunit – MD undergraduate program – Calcium homeostasis
- e. Internal Medicine Academic Half Day - Presenter
- f. Endocrinology Journal Club - Supervisor

*Osteoporosis Society of Canada (OSC) – Menopause program - tutor
OSC Bone Mineral Density Taskforce - member - revising OSC guidelines*

Oakville Bone Centre - Physician Education Program, coordinator

*University of Toronto - Bone and Mineral Group
Research grant applications reviewer*

Grant Reviewer for Physicians' Services Incorporated Foundation

Editorial Board member, Journal of Clinical Densitometry, Osteo Update

Reviewer for numerous journals including Acta Haematologica, Canadian Coordinating Office for Health Technology Assessment, Clinical Endocrinology, Fertility and Sterility, Future Medicine, JAMA, Journal of Bone and Mineral Research, Journal of Clinical Endocrinology and Metabolism, Journal of Molecular Biology Research, Lancet, Osteoporosis International, Society of Obstetrics and Gynecologists Canada, British Medical Journal, Canadian Medical Association Journal, Journal of Clinical Densitometry, Journal of General Internal Medicine, Journal of Obstetrics and Gynecology Canada, Nature, Journal of Rheumatology, European Journal of Endocrinology, Endocrine July – August 2002
*Consultant to Ontario Ministry of Health and Long-Term Care
Member of the Osteoporosis Action Plan Committee, Ontario Ministry of Health
Member of the Clinical Issues Committee, Ontario Ministry of Health*

June – September 2003 Member BMD testing payment rules subcommittee Ontario Ministry of Health

April 2005 Reviewer for Irish Health Research Board Grant programme

Sept 2005 – Present Editorial Consultant for American College of Physicians PIER Program – hypercalcemia module (Physicians Information and Education Resource)

2007 Quality Assurance – College of Physicians and Surgeons of Ontario – Peer Assessor

2013 Lead for Quality Improvement Resources Endocrinology Section, College of Physician and Surgeons of Ontario

INVITED PRESENTATIONS: (Since 1995)

*April 1995 University of Western Ontario
Regional Symposium on Skeletal Biology and Metabolic Bone Disease
Poster Presentation "Osteoporosis Associated With Pregnancy"*

May 1995 University of Toronto
Course Faculty on "Perimenopausal Update Women in the Transition Years"
Nominated for Award of Excellence

December 1995 McMaster University
Regional Endocrine Grand Rounds "Bisphosphonate use in the 90's"

March 1996 Mississauga General Hospital, Family Practice Rounds
"New Perspectives in Osteoporosis"

March 1996 Oakville Trafalgar Memorial Hospital, Continuing Medical Education lecture
"New Frontiers in Osteoporosis Management"

March 1996 Oakville Trafalgar Memorial Hospital
Department of Medicine Rounds - "Bones and Bisphosphonates"

May 1996 University of Toronto, Wellesley Hospital
Endocrine Rounds - "Advances in Management of Bone Disease"

September 1996 McMaster University
Regional Geriatric Grand Rounds - "Bone Disease in the Elderly"

September 1996 State University of New York at Syracuse
Course Faculty on "Regional Symposium - Update on Women's Health"

October 1996 University of Binghamton, Binghamton, New York
Obstetrics and Gynaecology Grand Rounds
"Emerging Therapies for Postmenopausal Osteoporosis"

October 1996 Joseph Brant Memorial Hospital, Burlington
Department of Family Medicine - "Advances in Osteoporosis Management"

February 1997 University of Western Ontario, London, Ontario
Regional Osteoporosis Workshop - "Comprehensive Management of Osteoporosis"

March 1997 Oakville Trafalgar Memorial Hospital
Continuing Medical Education - "Update on the Fracture Intervention Trial"

April 1997 Credit Valley Hospital, Mississauga
Department of Family Medicine - "Current Management of Osteoporosis"

January 1998 Oakville Trafalgar Memorial Hospital, Department of Medicine Grand Rounds
"Hormone Replacement Therapy and Effects on Bone and Lipids"

January 1998 McMaster University, Regional Endocrine Grand Rounds
"Medical Management of Primary Hyperparathyroidism"

January 1998 McMaster University
Medical Grand Rounds - "Bisphosphonates in Primary Hyperparathyroidism"

March 1998 McMaster University
Geriatric Grand Rounds - "Primary Hyperparathyroidism - 1998"

March 1998 *McMaster University, Regional Endocrine Rounds*
"Hormone Replacement Therapy & SERMS - Effect on Bone and Lipids"

April 1998 *Universite de Montreal, Department of Obstetrics and Gynecologie*
Continuing Medical Education
"Prevention and Treatment of Osteoporosis in Post-Menopausal Women"

April 1998 *Joseph Brant Memorial Hospital*
Continuing Medical Education - "Advances in Osteoporosis Research"

May 1998 *Association Des Medecins Endocrinologues du Quebec*
Seizieme Reunion Scientifique Annuelle - "Prévention of Osteoporosis"

June 1998 *Georgetown District Hospital*
Continuing Medical Education - "Prevention of Osteoporosis"

June 1998 *Oakville Trafalgar Memorial Hospital*
Continuing Medical Education - "Post-menopausal health"

August 1998 *International Society for Clinical Densitometry*
Certification Course Faculty – Vancouver - "Hyperparathyroid Bone Disease"

October 1998 *Oakville Trafalgar Memorial Hospital*
Continuing Medical Education – "Post-menopausal Health"

January 1999 *5th Annual Scientific Meeting of ISCD & College of*
Physicians and Surgeons of Columbia University
Course Faculty on "Clinical Integration of Peripheral
and Central Bone Mass Measurement"

Podium presentation on "Primary Hyperparathyroidism 1999"

Poster presentation on "Compliance and Tolerability of
therapy in Post-Menopausal Osteoporosis"

February 1999 *Oakville Trafalgar Memorial Hospital*
Continuing Medical Education - "What's New in Steroid-Induced Osteoporosis"

February 1999 *Joseph Brant Hospital*
Department of Family Medicine - "Advances in Bone Densitometry"

March 1999 *Joseph Brant Hospital*
Department of Medicine Rounds - "Management of Secondary Osteoporosis"

April 1999 *Joseph Brant Hospital, Department of Family Medicine - Osteoporosis Case Studies*
"Bone Densitometry Utilization"

June 1999 *Bone and Mineral Group of the University of Toronto*
Poster presentation "Impact of Patient Education Program on
Compliance of Drug Therapy in Post-menopausal Osteoporosis"
By M. Ahmed and A.A. Khan

September 1999 *Federation of Medical Women – Annual Meeting
“Advances in Osteoporosis Research”*

October 1999 *Etobicoke General Hospital
Osteoporosis Journal Club - “Advances in Bone Densitometry”*

November 1999 *Canada-wide Osteoporosis Symposium jointly sponsored by OSC/ISCD/SOGC/CAR/OAR and
McMaster University
Chair, Planning Committee
a) Podium Presentation – Hyperparathyroid Bone Disease
b) Podium Presentation – Advances in Peripheral Densitometry*

January 2000 *Society of Obstetrics and Gynecologists of Canada – CME event
“Diagnosis of Osteoporosis”*

February 2000 *Peel Hospital Grand Rounds
“Advances in Osteoporosis Management”*

March 2000 *Co-Chair ISCD/IOF (International Osteoporosis Foundation)
Bone Densitometry Symposium London, England
Podium Presentation – Reporting of Bone Density Studies*

March 2000 *Oakville Trafalgar Memorial Hospital
Continuing Medical Education – “Osteoporosis in Men”*

March 2000 *Osteoporosis Society of Canada – Peterborough Chapter
“Advances in Osteoporosis Research”*

April 2000 *Oakville Trafalgar Memorial Hospital
Department of Medicine Rounds - “Glucocorticoid-induced Osteoporosis”*

May 2000 *ISCD Annual Meeting Rio, Brazil- May 11, 2000
Podium presentation “Skeletal Effects of Primary Hyperparathyroidism”*

June 2000 *Halton Healthcare Services CME
“Osteoporosis 2000 - Role of Calcitonin”*

June 2000 *McMaster University – Grand Medical Rounds
“Primary Hyperparathyroidism 2000”*

September 2000 *University of Calgary – Foothills Osteoporosis Update
“Diagnosis of Osteoporosis”*

September 2000 *Federation of Medical Women Annual Meeting
“Advances in Osteoporosis Therapy”*

October 2000 *Milton Hospital CME Rounds
“HRT – Advances in Research”*

November 2000 *Halton Health Care Services Continuing Education Rounds
“Fractures and Bone Pain”*

November 2000 *University of Hong Kong, National Osteoporosis Symposia
"Skeletal Effects of Parathyroid Excess"*

November 2000 *University of Hong Kong, Department of Medicine
"Skeletal Effects of Parathyroid Bone Disease"*

November 2000 *University of Hong Kong, Department of Medicine
"Bone Densitometry – Role in Diagnosis and Management"*

November 2000 *University of Hong Kong, Department of Medicine
"Hyperparathyroidism – Advances in Management"*

November 2000 *University of Hong Kong, Department of Medicine
National Bone Symposium
"Calcitonin – Antifracture Efficacy"*

January 2001 *Department of Medicine Rounds, Halton Health Care Services
"Primary Hyperparathyroidism 2001"*

February 2001 *Grand Rounds, Greater Niagara Hospital
"Advances in Bisphosphonates"*

March 2001 *Society of Obstetricians and Gynaecologists of Canada, Annual Meeting
San Jose, Costa Rica
"Bone Densitometry 2001"*

March 2001 *Annual Scientific Meeting jointly sponsored with the College of Physicians and Surgeons
Columbia University, Dallas, Texas
"International Bone Densitometry Initiatives"*

March 2001 *ISCD Certification Course, Pittsburgh, Pennsylvania
"Osteoporosis – Diagnosis and Therapeutics"*

May 2001 *Chair, Osteoporosis in Canada Symposia hosted by Osteoporosis Society of Canada, ISCD,
SOGC, and McMaster University
"Parathyroid Bone Disease"
"Canadian ISCD Standards"
ISCD Course Director*

September 2001 *"Advances in Male Osteoporosis"
Grand Rounds
Peel Memorial Hospital*

September 2001 *"Management of Osteoporosis"
Citywide Endocrine Rounds
McMaster University*

October 2001 *Poster presentation at plenary session
American Society for Bone and Mineral Research 23rd Annual Meeting
Phoenix, Arizona
"A Double Blind Randomised Placebo Controlled Trial of Alendronate in Primary
Hyperparathyroidism"*

November 2001 *“Osteoporosis: Who to Screen, How to Treat.”*
Podium Presentation
Society of Obstetricians and Gynecologists of Canada 20th Ontario CME Program,
Toronto

November 2001 *Course Director – ISCD Certification Course*
Toronto, Ontario

November 2001 *“Clinical Applications of Bone Densitometry – Diagnosis”*
Podium Presentation
ISCD Certification Course, Toronto

November 2001 *Canada Wide Osteoporosis Symposia sponsored by OSC, ISCD, University of Western*
Ontario, “Calcitonin Evidence-Based Review”
Podium Presentation, Toronto

November 2001 *Canada Wide Osteoporosis Symposia (OSC, ISCD, UWO)*
“Canadian ISCD Standards”
Podium Presentation, Toronto

January 2002 *North York General Hospital*
Family Medicine Clinic Day
“Bare Bones: Revised Guidelines for Densitometry”
“Advances in Osteoporosis Therapy”

February 2002 *“Parathyroid Disease in the Elderly”, Geriatric Grand Rounds*
McMaster University

April 2002 *National Institute of Health, Bethesda, USA*
Asymptomatic Primary Hyperparathyroidism
Consensus Conference
Chair – Medical Management in 2002
Podium presentation - “Alendronate in Primary Hyperparathyroidism Two-Year Data”

April 2002 *Halton Health Care Services – CME Rounds*
“A New Chapter in Osteoporosis: Updates in the Diagnosis and Treatment”

May 2002 *Chair’s Grand Rounds, McMaster University*
“Primary Hyperparathyroidism: Update from the NIH Consensus Conference 2002”

June 2002 *Public Forum – Halton Health Care Services*
“Treating Osteoporosis in Men.”

September 2002 *Podium presentation*
“Alendronate in Primary Hyperparathyroidism”
American Society of Bone and Mineral Research 24th Annual Meeting
San Antonio, Texas

October 2002 *Podium presentation “Advances in Osteoporosis Research”*
Osteoporosis Society of Canada Operations Group Meeting

October 2002 *Citywide Endocrine Rounds McMaster University*
“The Calcium Sensing Receptor and Parathyroid Disease”

October 2002 *Universite de Montreal Faculty of Medicine Continuing Health Education
"Osteoporosis: It's Time for Action!"*

November 2002 *CME Rounds Halton Health Care Services
"Bridging the Gap – What to do After a Fragility Fracture"*

November 2002 *CME Rounds Halton Health Care Services
"New OSC Guidelines"*

November 2002 *Toronto Chapter OSC
Keynote Speaker*

November 2002 *Citywide Endocrine Rounds McMaster University
"Primary Hyperparathyroidism: New Canadian & NIH Guidelines"*

November 2002 *Podium presentation "Advances in Therapies"
OSC Biannual Canada-wide symposia
University of British Columbia*

November 2002 *ISCD Program Director
ISCD Lecture "Osteoporosis Pathophysiology"*

February 2003 *Podium presentation "Bone Density in Premenopausal Women"
Annual Scientific Meeting of International Society for Clinical Densitometry
Los Angeles, California February 12-16, 2003*

February 2003 *Chair of session "Secondary Causes of Osteoporosis"
Annual Scientific Meeting of International Society for Clinical Densitometry
Los Angeles, California February 12-16, 2003*

February 2003 *Grand Rounds, Department of Medicine Credit Valley Hospital
Podium presentation "2002 OSC Guidelines"*

March 2003 *Internal Medicine Rounds, Halton Healthcare Services
Primary Hyperparathyroidism (PHPT): A State of the Art Lecture*

June 2003 *Department of Medicine Rounds, Halton Healthcare Services
Osteoporosis in Men, Premenopausal Women and Steroid Induced Bone Loss*

June 2003 *Osteoporosis in Canada Symposia – University of Toronto
Course Director
ISCD Lecture "Bone Densitometry for the Diagnosis of Osteoporosis"
ISCD Lecture "Clinical Management of Osteoporosis"
ISCD Lecture "Principles of Reporting DXA Scans"*

July 2003 *Position Development Conference – ISCD Cincinnati
Keynote Luncheon Speaker, "Canadian Standards for Bone Mineral Density in
Premenopausal Women, Men, and Children"*

July 2003 *4th Annual Rheumatology Update
Podium Presentation "Low BMD in Premenopausal Women"*

September 2003 Department of Family Medicine Rounds, St. Joseph's Healthcare, Hamilton
Calcium & Parathyroid Disorders

September 2003 Department of Family Medicine Rounds, William Osler Health Centre
Advances in Osteoporosis Research

September 2003 1st Annual General Meeting of the Osteoporosis Society of Canada Niagara Chapter
Keynote Speaker
"Osteoporosis, Latest Treatments"

September 2003 Citywide Endocrine Rounds
McMaster University
"Advances in Hypercalcemia"

September 2003 A Double Blind Randomized Placebo Controlled Trial of Alendronate in Primary Hyperparathyroidism
Plenary Poster Presentation – Abstract 663**
ASMBR 25th Annual Meeting, September 19-23, 2003, Minneapolis, MN
**This paper was selected for the best abstracts plenary session

October 2003 Eastern Great Lakes, Society of Nuclear Medicine 23rd Annual Meeting
Podium Presentation
"Advances in Osteoporosis Management"

October 2003 Canadian Society of Endocrinology and Metabolism
"Canadian Position Paper on Primary Hyperparathyroidism"

October 2003 Lincoln County Academy of Medicine Annual Clinic Day

November 2003 Town of Oakville Education Session
"Advances in Osteoporosis"

December 2003 First Pan Arab Bone Density Certification Course Organized jointly by the Pan Arab
Osteoporosis Society (PAOS) & the Jordanian Osteoporosis Prevention Society (JPOS) &
the International Osteoporosis Foundation
a) Podium presentation – Osteoporotic fracture: radiographic assessment methods
b) Podium presentation – Clinical assessment of osteoporosis
c) Podium presentation – Diagnostic use of bone densitometry
d) Podium presentation – Fracture risk assessment
e) Podium presentation – Monitoring skeletal changes by densitometry

January 2004 ISCD Annual International Scientific Meeting, Miami Florida
a) Podium presentation – Canadian BMD Standards-Key Practical Points
b) Poster presentation – Double Blind Randomized Trial of Alendronate in Primary
Hyperparathyroidism

February 2004 CME Rounds Halton Health Care Services
"Practical Tips on Osteoporosis Management: Case Based Learning"

April 2004 Women's Health Expo, Rouge Valley Centenary Hospital, Scarborough, ON
"Advances in Postmenopausal Health"

April 2004 McMaster University CME for specialists Sunnybrook Estates
"Canadian Standards for Bone Mass Measurement"

April 2004 *McMaster University Geriatric Grand Rounds*
"Bone Mass Measurement Canada: 2004 Standards"

April 2004 *St. Joseph's Healthcare McMaster University Medical Grand Rounds*
"Hypocalcemic Crisis: A Case-Based Presentation and State of the Art Lecture"

April 2004 *St. Joseph's Hospital, University of Toronto, OB/GYN Rounds*
"BMD Testing in Canada 2004"

April 2004 *Osteoporosis Society of Canada Niagara Chapter Public Forum*
"Osteoporosis and You"

May 2004 *Halton Healthcare Services Public Forum*
"Postmenopausal Health"

June 2004 *International Congress of Radiology and ISCD Bone Densitometry Course – Montreal*
a) *Overview of Osteoporosis*
b) *Clinical Utility of Bone Densitometry*
c) *Principles of DXA Scan Interpretation*

September 2004 *McMaster University Department of Radiology, Visiting Professor*
Podium presentation – Bone Mass Measurement – Advances in Research

September, 2004 *University of Calgary and ISCD Bone Densitometry Course – Podium Presentations*
a) *Overview of Osteoporosis*
b) *Diagnosis of Osteoporosis*
c) *Pitfalls in interpretation*

September, 2004 *Practical Approach to osteoporosis in Men*
Halton Health Care Services, Grand Rounds

September, 2004 *Regional Endocrine/Metabolic Rounds*
Monthly City-Wide Grand Rounds
"Calcium Emergencies"

October 14, 2004 *Chair's Rounds, McMaster University "Hypercalcemia 2004"*

October 19, 2004 *Regional Endocrine/Metabolic Grand Rounds –McMaster University*
"Anabolic Agents for Osteoporosis – 2004"

October 19, 2004 *Halton Healthcare Services, CME lecture, "Canadian Bone Density Standards; 2004 Guidelines"*

October 23, 2004 *Canadian Association of Radiology Scientific Meeting, St. Catharines, Ontario*
"Bone Mass Measurement"

October 29, 2004 *Meet the Professor Session, Canadian Society of Endocrinology and Metabolism,*
Quebec City, "Primary Hyperparathyroidism"

November 5, 2004 *St. Michael's Hospital, Grand Rounds, Dept. OB/GYN, University of Toronto*
"Anabolic agents for the treatment of osteoporosis"

November 25, 2004 *The Niagara Orthopaedic Association, St. Catharines, Ontario
"Osteoporosis and the Bisphosphonates – Part 2"*

November 25, 2004 *The Society of Obstetricians and Gynaecologists of Canada
Annual Scientific Meeting, Toronto, Ontario
"Bone Health: When does the Clock Start Ticking"
Osteoporosis therapies; "Best Practice sermon"
"Non HRT options in Osteoporosis Management"*

January 5, 2005 *University of Western Ontario, London, Ontario. Endocrine Rounds
"Canadian guidelines for management of primary hyperparathyroidism"*

February 17, 2005 *International Society of Clinical Densitometry
Annual Meeting 2005, New Orleans, Louisiana
"ISCD Positions Statements"*

April 6-7, 2005 *Invited Chair and Guest Speaker, Riyadh, Saudi Arabia
International Osteoporosis Foundation, (IOF) and ISCD, Bone Densitometry Symposia
and Certification course,*

May 3, 2005 *University of Calgary accredited program
"Breast Cancer, Aromatase Inhibitors and boneless"*

May 17, 2005 *McMaster University Medical Centre, Regional Endocrine and Metabolic Rounds
"Anabolic Agents and Strontium"*

June 2, 2005 *Vitamin D MetaForum – by Osteoporosis Society of Canada, Toronto, Ontario
Key Note Speaker, "Vitamin D Insufficiency, Pathophysiology and Management"*

June 10, 2005 *Oakville Trafalgar Memorial Hospital, Department Of Medicine – Continuing Medical
Education Rounds, "Calcium Emergencies: Hyper and Hypo" Speaker*

June 25-26, 2005 *McMaster University, ISCD Bone Densitometry Course
Chair and Speaker*

June 25, 2005 *Chair and Speaker, Osteoporosis Symposium sponsored by Osteoporosis Society of
Canada and McMaster University*

July 16, 2005 *2005 Position Development Conference ISCD, Vancouver, BC
Presentation of Canadian BMD Standards*

July 17-18, 2005 *ISCD Bone Densitometry Course, Vancouver, BC- Podium Presentations
a) ISCD Introduction and Objectives
b) Overview of Osteoporosis
c) Diagnosis of Osteoporosis
d) Reporting of BMD*

September, 2005 *Halton Health Care Services, CME Rounds "Anabolic Agents"*

September, 2005 *Osteoporosis Society of Canada Public Symposia
"New Research in Osteoporosis Therapies"*

October 1, 2005 St. Michael's Hospital, University of Toronto Outreach Program
"Bone densitometry – 2005"

October 24, 2005 Ontario Long Term Care Physicians Annual Meeting, Podium presentation
"Osteoporosis and Anabolic Therapies"

November 4, 2005 University of Ottawa Family Practice Rounds
"Anabolic Agents"

November 4, 2005 Riverside Hospital, Ottawa
"What's new in the OSC Guidelines, expected changes?"

November 8, 2005 Joseph Brant Memorial Hospital
Grand Rounds
"Osteoporosis in Men"

November 9, 2005 St. Joseph's Healthcare, Grand Rounds, McMaster University
"Hypercalcemia 2005"

November 10, 2005 University of British Columbia, Dept of OB/GYN
31st Annual D.A. Boyes Society Meeting
Podium presentation "Low BMD in premenopausal women"

November 19, 2005 Osteoporosis Symposium 2005 Where We Stand, The Michener Institute,
Osteoporosis Society of Canada
"Recommendations for BMD Reporting"

February 1-4, 2006 International Society of Clinical Densitometry
Annual Scientific Meeting, San Diego, USA
Poster presentation "Alendronate Improves BMD in Men with Primary
Hyperparathyroidism" by A. Khan, Z. Syed, S. Dubois, T. Standish

Podium presentation "Canadian Standards for Skeletal Assessment in Secondary
Osteoporosis "

Moderator "World Health Organization Definition of Osteoporosis – International
implications"

February 9, 2006 Chair's Medical Grand Rounds, Faculty of Health Sciences Department of Medicine
McMaster University "Parathyroid Disease in 2006",

February 13, 2006 2005 OSC Guidelines, "What's New in Diagnosis & Treatment?", Hopital Sacre-Coeur,
Salle Emilie Gamelin, Montreal

February 14, 2006 Gynecology Grand Rounds, Hopital St-Luc, Montreal, "Anabolic Therapies"
University of Montreal Grand Rounds, Hopital Du Haut-Richelieu

February 15, 2006 Gynecology Grand Rounds, "Anabolic Therapies in 2006; The clinical management of
severe osteoporosis", Centre Hospitalier Regional de Trois-Rivieres

February 18-19, 2006 *International Society of Clinical Densitometry and the University of Kuwait, Kuwait Bone Densitometry National Symposia*
Podium presentations:
General Session “X-ray Science, Radiation Safety & Quality Assurance”
Clinician Course “Clinical Utility of Bone Densitometry”, “Monitoring with Bone Densitometry”, “Principles of Reporting DXA Scans”

February 20, 2006 *ISCD Vertebral Fracture Assessment Course, University of Kuwait, Kuwait*

March 7, 2006 *Primary Care Rounds, Halton Healthcare Services, “Parathyroid Disease: Diagnosis and Management in 2006”*

April 8, 2006 *The Society of Obstetricians and Gynaecologists of Canada, Annual Scientific Meeting, Podium presentation, “Anabolic Agents”, Toronto, ON*

April 22-23, 2006 *ISCD Bone Densitometry Course, Clinician Course*
“Bone Densitometry for Diagnosis of Osteoporosis”,
“Principles of Reporting DXA Scans”, Halifax, NS

April 22, 2006 *Osteoporosis Canada Scientific Symposia, Osteoporosis: What’s Now? What’s New?, “Recommendations for BMD Reporting: based on recent publication”, Halifax, NS*

May 4, 2006 *Credit Valley Hospital Family Medicine Rounds, “Parathyroid disease – New Canadian Guidelines”*

May 30, 2006 *Family Practice Grand Rounds, “Parathyroid disease”, Joseph Brant Hospital Burlington, Ontario*

June 6, 2006 *Dept. of Medicine Grand Rounds, “Anabolic Therapy in 2006”, Credit Valley Hospital Mississauga, Ontario*

June 3, 2006 *IOF International Osteoporosis Foundation Scientific Meeting, “BMD response to Alendronate in Men with Primary Hyperparathyroidism”, Toronto, Ontario*

June 16, 2006 *McMaster University and University of Western Ontario, “Endocrine Update”, Hamilton, ON - Course Co-Director and speaker*
a) *Primary Hyperparathyroidism-Pathophysiology and Medical Management*
b) *Renal Osteodystrophy*
c) *ISCD Position Statements and Osteoporosis Canada BMD Reporting Guidelines*

June 26, 2006 *Annual Scientific Meeting of the Society of Obstetricians and Gynecologists of Canada, “Osteoporosis in the early postmenopausal woman” Plenary Session, Vancouver, BC*

July 15-16, 2006 *ISCD Certification Course Faculty, University of Alberta, AB*

September 12, 2006 *Osteoporosis Society of Canada Public Forum, Kitchner, ON*

September 15-19, 2006 *ASBMR 28th Annual Meeting, “Alendronate in Premenopausal Women and Men” Philadelphia, Pennsylvania, USA*

September 2006 *Ontario Society of Oral and Maxillofacial Surgeons, Toronto, ON*
Podium presentation – “ONJ update”

September 29, 2006 Nephrology Rounds, "Renal Osteodystrophy", St. Josephs Healthcare, Hamilton, Ontario

October 18, 2006 St. Joseph's Hospital Grand Rounds, "Hypercalcemia: Common and rare causes" Hamilton, Ontario

October 18, 2006 Canadian Society of Endocrinology and Metabolism Professional Conference 2006 Toronto, ON Poster presentation - "Alendronate in Primary Hyperparathyroidism: Efficacy in Men and Premenopausal Women"

November 18, 2006 Michener Osteoporosis Symposia, Osteoporosis Canada educational program "Osteoporosis is Men" Podium Presentation

November 22, 2006 Spanish Congress Annual Scientific Meeting, SEIOMM, 11th Congress Meeting, Malaga Spain, Delivered Plenary lecture for Inaugural ceremony "Premenopausal Osteoporosis"

November 30, 2006 The Society of Obstetricians and Gynaecologists of Canada, Toronto, ON "Management of Low BMD in Premenopausal Osteoporosis"

December 15, 2006 Chair's Grand Medical Rounds, Henderson General Hospital, McMaster University, Hamilton, Ontario "Hypercalcemia: Common and rare causes"

March 15, 2007 ISCD Annual Scientific Meeting Tampa, Florida presentation " Guidelines on the utilization of DXA in secondary causes of osteoporosis - renal osteodystrophy, vitamin D deficiency states, primary hyperparathyroidism"

March 13-14, 2007 Faculty member for ISCD Bone Densitometry Certification course - Tampa, Florida

March 28, 2007 Institute for Clinical Evaluative Sciences/Clinical Epidemiology Unit (ICES/CEU) Rounds, Ground Conference Centre, Toronto, Ontario "Hypercalcemia: Common and rare causes"

April 17, 2007 Regional Endocrine/Metabolic Rounds, McMaster University Medical Centre, Hamilton, Ontario "Osteoporosis in premenopausal women and men"

April 20-21, 2007 3rd Annual Society of Obstetrics and Gynecology of Canada, (SOGC) Ontario CME Program, Toronto, ON "Management of Low BMD in Premenopausal Women"

May 25, 2007 University of Western Ontario and McMaster University, Canadian Endocrine Update, London, ON – Program Co-chair and speaker Podium presentation "Premenopausal Osteoporosis"

May 26, 2007 University of Western Ontario, The Diagnosis and Management of Thyroid Cancer Symposium, London, ON, "Complications of thyroid cancer therapy: hypocalcemia"

June 10, 2007 65th Annual Canadian Association of Medical Radiation Technologist, (CAMRT) Ottawa, ON, "Technical Aspects of BMD"

June 19, 2007 Rheumatology Journal Club, Ottawa, ON "What's New in Osteoporosis"

June 20, 2007 *Ottawa Civic Hospital Regional OB/GYN Grand Rounds "Management of Osteoporosis in the early postmenopausal female"*

September 25, 2007 *"ONJ and More: What's New in Osteoporosis", Halton Healthcare Services Rounds*

October 12, 2007 *Department of Medicine Grand Rounds HHS "Osteoporosis due to Medical Causes"*

October 2007 *Ontario Long Term Care Physicians Scientific Symposia "Advances in Osteoporosis"*

October 19, 2007 *Stratford General Hospital Grand Rounds "New therapies for Osteoporosis"*

January 9, 2008 *Medical Grand Rounds at St. Joseph's Healthcare "Osteonecrosis of the Jaw—important new developments in an old disease"*

February 1, 2008 *Milton District Hospital Grand Rounds Update on Osteoporosis Therapies*

February 16, 2008 *Chair and speaker Hamilton Health Fair "Vitamin D and Bone Disease"*

March 4, 2008 *International Osteoporosis Foundation Bone Symposia Dubai, United Arab Emirates –*
- *"Osteonecrosis of the Jaw – New Understanding in an Old Disease"*
- *"Advances in Bone Densitometry"*

March 5, 2008 *King Saud University, Riyadh, Saudi Arabia –*
- *"Long-Term Side Effects of Bisphosphonate Therapy"*
- *"Advances in Management of Osteoporosis"*

March 15, 2008 *International Society of Clinical Densitometry Annual Scientific Meeting, San Francisco, California "Long-Term Effects of Bisphosphonate Therapy"*

May 1, 2008 *Section on Nuclear Medicine, Hilton Toronto, "Osteoporosis, BMD, and Newer Therapeutic Interventions"*

May 13, 2008 *Chair, International Workshop on Primary hyperparathyroidism AACE 17TH Annual Meeting and Clinical Congress, Orlando, FL. "Medical Approaches- Bisphosphonates," - podium presentation*

May 24 -28, 2008 *Invited guest speaker at 35TH European Symposium on Calcified Tissues Barcelona, Spain "Premenopausal osteoporosis – diagnosis and assessment"*

May 30 – Jun 1, 2008 *Chair, Canadian Endocrine Update, McMaster University, University of Western Ontario, "Advances in Medical Approaches to Primary Hyperparathyroidism," "Osteonecrosis of the Jaw-New Developments in an Old Disease," "Advances in Therapy," "ISCD International Society of Clinical Densitometry-BMD Certification Course for Clinicians"*

Jun 11, 2008 *"Hypercalciuria and Renal Stones," McMaster Institute of Urology, Grand Rounds*

Jun 13, 2008 *"Bone Health in Breast Cancer Survivors," University of Toronto*

Aug 12, 2008 *"New Guidelines for Primary Hyperparathyroidism," MD Anderson Cancer Centre, Houston, Texas*

- Sept 13, 2008 "New Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism," American Society for Bone and Mineral Research, Montreal, Quebec.
- Sept 23, 2008 "Update in Osteoporosis," Continuing Medical Education, Halton Healthcare, Oakville
- Nov 15, 2008 "Men & Osteoporosis," Michener and Osteoporosis Canada CME, Toronto
- Dec 5, 2008 "Osteoporosis Diagnosis and Treatment in Premenopausal Women," The Society of Obstetricians and Gynaecologists of Canada, Toronto
- Jan 15, 2009 "Advances in Osteoporosis Management" AFHTO-Association of Family Health Teams of Ontario, Toronto
- Jan 29, 2009 "Osteoporosis: Current Challenges and New Treatments," University of Ottawa, Women's Health, Endocrinology and Rheumatology Rounds, Ottawa
- Feb 4, 2009 "New Guidelines for PHPT," Chair of Medicine-Grand Medical Rounds, McMaster University, Hamilton
- Mar 13, 2009 "Meet the Professor – New International Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism," ISCD-IOF Joint Meeting March 11-14, 2009, Orlando, FL
- Mar 10-11, 2009 "Overview of Osteoporosis," ISCD Bone Densitometry Course, Orlando, FL
- "Use of Bone Densitometry for the Diagnosis of Osteoporosis," ISCD Bone Densitometry Course, Orlando, FL
- "Introduction to: Vertebral Fracture Assessment," ISCD Bone Densitometry Course, Orlando, FL
- Mar 14, 2009 "Technical Aspects of VFA Imaging," ISCD Vertebral Fracture Assessment Course, Orlando, FL
- "Principles of Reporting VFA," ISCD Vertebral Fracture Assessment Course, Orlando, FL
- Mar 26, 2009 "Osteoporosis: Current Challenges and New Treatments," Osteoporosis Society of Canada, Kingston
- Mar 27, 2009 "Primary Hyperparathyroidism – New Guidelines," St. Michael's Hospital Osteoporosis Outreach Program, Park Hyatt Toronto, Toronto, Ontario
- April 2, 2009 "Treatment of Acute Severe Hypercalcemia," McMaster University Internal Medicine Review Course, Hamilton, Ontario
- April 9, 2009 "Advances in Osteoporosis Therapy," Credit Valley Hospital Rounds, Mississauga, Ontario
- April 17, 2009 "TZD's and Bone Disease: Affecting clinical decisions in osteoporosis patients?" Canadian Endocrine Update, London, Ontario
- April 18, 2009 "Osteoporosis in Pre-menopausal Women," Canadian Endocrine Update,

London, Ontario

"ISCD Bone Densitometry Certification Course," Canadian Endocrine Update, London, Ontario

April 19, 2009

"Use of Bone Densitometry for the Diagnosis of Osteoporosis, ISCD Bone Densitometry Course, London, Ontario

"Principles of DXA Scan Interpretation," ISCD Bone Densitometry Course, London, Ontario

"Principles of Reporting DXA Scans," ISCD Bone Densitometry Course, London, Ontario

"Vertebral Fracture Assessment," ISCD Bone Densitometry Course, London, Ontario

May 1, 2009

"Bisphosphonate Associated Osteonecrosis of the Jaw", Canadian Dental Association Annual Scientific Meeting

May 5, 2009

"Advances in Osteoporosis in 2009", Osteoporosis Canada, Halton Healthcare Services public forum

May 10, 11, 12 2009

*Kuwait Ministry of Health, ISCD Certification Course, Kuwait City, Kuwait
Kuwait Ministry of Health, ISCD Vertebral Fracture Assessment Course, Kuwait City, Kuwait*

May 22, 2009

"Osteoporosis in Men", Oakville Trafalgar Memorial Hospital Rounds

May 27, 2009

"Advances in Osteoporosis," St. Catharines Family Physicians, St. Catharines, Ontario

June 18, 2009

"Osteoporosis in Perimenopausal Women" Post-graduate Course Director, SOGC Annual Meeting, Halifax, Nova Scotia

June 25, 2009

"Advances in Osteoporosis," Trillium Hospital Rounds, Mississauga, Ontario

July 22, 2009

"Advances in Osteoporosis", Credit Valley Hospital Family Medicine Residency Program

September 8, 2009

"Advances in Osteopenia", Halton Healthcare Services Medical Rounds

September 12, 2009

ASBMR Podium Presentation, "Incidence of Bisphosphonate Associated ONJ in Canada," Denver Colorado USA

October 13, 2009

"Optimizing Osteoporosis Management", Hamilton Community Health Care CME Series, Hamilton

October 18, 2009

"An Update on Diagnosis and Treatment of Hyperparathyroidism", Plenary session, Canadian Society of Endocrinology and Metabolism (CSEM), Annual Professional Conference, Montreal, Quebec

October 27, 2009

"PHPT new guidelines", McMaster University, Endocrinology Journal Club Supervisor

November 12, 2009

"Advances in Osteoporosis", Windsor Endocrinology Rounds

November 17, 2009 "Osteoporosis in Men", Halton Healthcare Services Grand Rounds

November 17, 2009 "New Treatments for Osteoporosis", Public Education Forum 2009, Hamilton, Ontario, Osteoporosis Canada

November 20, 2009 "Osteoporosis Advances in diagnosis and management", 5th Annual Update in Endocrinology & Diabetes, University of Ottawa, Ottawa, Ontario

November 20, 2009 "Current Medical Options for hypoparathyroidism", Hypoparathyroidism Scientific Session, Co-Chair and Speaker, Newark, New Jersey

December 5, 2009 "Osteoporosis: What's Hot, What's Not", Podium Presentation, SOGC, 28th Ontario CME, Toronto, Ontario

January 15, 2010 "New Guidelines for Primary Hyperparathyroidism", CityWide Endocrine Rounds at University of Toronto, Toronto, Ontario

February 1, 2010 "New Approaches to Osteoporosis Management", Credit Valley Hospital Department of Medicine Grand Rounds

March 27, 2010 "What is the Optimal Management of Osteoporosis: Old and New Therapies", 2nd McMaster University Review Course in March 24 – 27, 2010, Hamilton, Ontario

April 9-11, 2010 Canadian Endocrine Update, Co-Chair, McMaster University, Hamilton, Ontario

April 9, 2010 "Hypercalcemia – challenges in diagnosis", Canadian Endocrine Update, Speaker, McMaster University, Hamilton, Ontario

April 9, 2010 "RANK Ligand pathway - a novel target for intervention", Canadian Endocrine Update, Speaker, McMaster University, Hamilton, Ontario

April 10, 2010 "Osteonecrosis of the Jaw (ONJ) Guidelines", Canadian Endocrine Update, Speaker, McMaster University, Hamilton, Ontario

April 10/11, 2010 ISCD Bone Densitometry Certification Course, Course Faculty, McMaster University, Hamilton, Ontario

April 23, 2010 "When to Start Prescribing and What to Prescribe", Mature Women's Health Care, University of Toronto, Toronto, Ontario

May 29, 2010 "Hypercalcemia - Challenging cases and an Overview", Association des medecins endocrinologues du Quebec, Gatineau, Quebec

June 4-6, 2010 Society of Atlantic Rheumatologists (SOAR) Annual meeting, Liverpool, Nova Scotia
 "Premenopausal Osteoporosis"
 "Osteoporosis in Men"

June 2010 City Wide Endocrine Rounds, McMaster University, "New Guidelines for Primary Hyperparathyroidism"

September 17, 2010 "Medical Management of PHPT", Plenary Lecture, 12th International Workshop on Multiple Endocrine Neoplasia, September 16 – 18, 2010, Gubbio, Italy

October 2, 2010 "Osteoporosis Therapies", Endocrine Day, Chatham, Ontario

October 6, 2010 "New Treatments for Osteoporosis", Niagara Multidisciplinary Day

October 14, 2010 "New Approach to Fracture Risk Assessment", Credit Valley Family Medicine Rounds

October 14-15, 2010 ISCD Course Faculty, Toronto, Ontario

October 15, 2010 "Vitamin D – Evolution in Understanding", St. Joseph's Healthcare Family Medicine Rounds

October 16, 2010 ASBMR Poster Presentation, "ONJ incidence in Ontario with Bisphosphonate Use", Toronto, Ontario

October 20, 2010 "Parathyroid Disease and Osteoporosis", Osteoporosis Secondary Causes Symposia sponsored by McMaster University and Osteoporosis Canada

October 22, 2010 Canadian Society of Endocrinology and Metabolism, Podium Presentation "New Approaches to Osteoporosis Diagnosis and Therapy", Edmonton, Alberta

October 29, 2010 "New Advances in Osteoporosis Diagnosis" Brampton Civic Hospital, Family Medicine Grand Rounds
Brampton, Ontario

November 7, 2010 "Bone China Tea", Public Forum, Osteoporosis Canada, Ancaster, Ontario

November 12, 2010 "New Advances in Osteoporosis ", Niagara Health System, Grand Medical Rounds
Niagara Falls, Ontario

November 30, 2010 "Osteoporosis 2010", Joseph Brant Hospital, General Internal Medicine Rounds
Burlington, Ontario

January 25, 2011 "Myths or Truths? Clarifying Recent Media Coverage on Osteoporosis Treatments and Adverse Effects", Center of Excellence for Skeletal Health Assessment (CESHA) Outreach Education, Mount Sinai Hospital,
Toronto, Ontario

March 15, 2011 Abstract: Exploring Differences in Bone Density and Structure between Patients on Bisphosphonates with Atypical Femur Fractures and other Populations, ECCEO11

April 7, 2011 Chair - ISCD Annual Scientific Meeting
Miami, Florida

April 14 - 15, 2011 Update in Gynaecology and Mature Women's Health, "Osteoporosis Update: New and Emerging Treatments and Controversies",
Toronto, Ontario

April 29 - 30, 2011 "Emerging Therapies for Osteoporosis", University of Western Ontario,
London, Ontario

May 6, 2011 "New and Emerging Treatments in Osteoporosis", Primary Care Today,
Toronto, Ontario

May 17, 2011 Halton Healthcare Grand Rounds - "Controversies in Osteoporosis Management"
Oakville, Ontario

May 27, 2011 "Controversies in Osteoporosis Management" and Chair of the Osteoporosis Symposia,
McMaster University/ISCD/Ontario Association of Medical Radiation Technologists/St.
Josephs Healthcare

May 28 - 29, 2011 ISCD Course Faculty and Chair, McMaster University
Hamilton, Ontario

September 16, 2011 ASBMR Atypical Femoral Fracture Poster Presentation

September 19, 2011 "Atypical Femoral Fractures: Radiographic and Histomorphometric Features in 9 Patients"
ASBMR,
San Diego, California

September 26, 2011 William Osler Hospital Grand Rounds - "Atypical Femoral Fractures"
Brampton, Ontario

October 4, 2011 "Controversies in Care" University of Toronto Rheumatology Journal Club
Toronto, Ontario

October 11, 2011 "Atypical Hip Fracture, ONJ, Drug Holidays and Osteoporosis Therapy" Halton Health Care
Services
Oakville, Ontario

October 18, 2011 "New research in osteoporosis" SOGC Public Forum

October 28, 2011 "Atypical Femoral Fractures: Radiographic and Histomorphometric Features in 9 Patients"
CSEM,
Toronto, Ontario

December 6, 2011 Credit Valley Hospital Grand Rounds - "An Update in Osteoporosis from the ASBMR and the
ACR Meetings"
Mississauga, Ontario

December 10, 2011 6th Annual Evolving Concepts in Renal Disease - "Metabolic Bone Disease/Osteoporosis"
Department of Nephrology - Humber River Regional Hospital, York Central Hospital
Toronto, Ontario

January 17, 2012 Joseph Brant Hospital Grand Rounds - "Osteonecrosis of the Jaw"
Burlington, Ontario

January 19, 2012 McMaster University Medical Centre Chair's Grand Rounds - "Hypoparathyroidism 2012:
New Evidence Based Recommendations"
Hamilton, Ontario

February 9, 2012 Schulich School of Medicine and Dentistry Endocrinology Grand Rounds - "Update on
Osteoporosis - New News from ASBMR"

February 21, 2012 City Wide Endocrine Rounds McMaster University "Controversies in Osteoporosis Care in
2012"

Hamilton, Ontario

- March 5-9, 2012 ISCD Bone Densitometry Course and Vertebral Fracture Assessment Course Faculty Annual Scientific Meeting Speaker "ONJ Guidelines" Los Angeles, California*
- March 22, 2012 Trillium Health Centre Family Practice Rounds - "Hypercalcemia" Mississauga, Ontario*
- March 28, 2012 Osteoporosis Canada Public Forum - "Vitamin D and Osteoporosis Medications" Ontario Science Centre, Toronto, Ontario*
- April 28, 2012 1st Canadian Endocrine Review Course - "Calcium Emergencies" - St. Josephs Hospital Hamilton, Ontario*
- May 26, 2012 Annual Meeting of Canadian Association of Oral and Maxillofacial Surgeons - "Osteonecrosis of the jaw - An International Perspective" Banff, Alberta*
- May 19, 2012 European Calcified Tissue Society - "Atypical Femoral Fractures and Bisphosphonate Use" Poster Presentation Stockholm, Sweden*
- May 25, 2012 American Association of Clinical Endocrinologists - "Atypical Femoral Fractures and Bisphosphonate use" - Poster Presentation Philadelphia, Pennsylvania, USA*
- June 5, 2012 Osteoporosis Symposia - "Adverse Effects of Treatment; Facts vs Myths" Toronto, Ontario*
- June 6-7, 2012 International Society for Clinical Densitometry - Bone Mineral Density Course for Physicians Hamilton, Ontario*
- June 9, 2012 The 6th International Hypoparathyroidism Patient Conference - "Advances and Challenges in Management of Hypoparathyroidism in 2012" Rockville, Maryland*
- June 15, 2012 A Day of Boomer Health for General Practitioners - "Is Your Postmenopausal Patient at Risk of Fracture? - Key therapeutic considerations for fracture prevention" Toronto, Ontario*
- June 26, 2012 American Academy of Oral Maxillofacial Pathology - "Persistent Exposed Non-Vital Bone Not Associated with Bisphosphonate Use" - Poster Presentation Minneapolis, Minnesota*
- July 19, 2012 Osteoporosis Update: New and Emerging Treatments and Controversies St. Josephs Hospital, Hamilton, Ontario*
- Sept 27 - Oct 1, 2012 International Osteoporosis Foundation
"Premenopausal Women and Low BMD" - Meet the Expert Sessions
"Hyperparathyroidism" - Plenary Session
"Advances in Anabolic Therapies for Osteoporosis" - Satellite Symposia
Dead Sea, Jordan*

Oct 12 - 15, 2012 *American Society of Bone and Mineral Research - Chair*
"Atypical Femoral Fractures: Radiographic and Histomorphometric features in 12 patients"
- Poster Presentation
"Hip structural Analysis of Patients with Atypical Femur Fractures: Data from the Ontario Cohort" - Poster Presentation
"Effect of Teriparatide on Fracture Healing in Patients with Non-displaced Incomplete Atypical Femoral Fractures" - Poster Presentation
"Oral Sequestration Not Associated with Bisphosphonate Use" - Poster Presentation
Minneapolis, Minnesota

November 3, 2012 *Winnipeg CME Family Medicine Day "Osteoporosis Advances in Care"*
Winnipeg, Manitoba

November 7, 2012 *Chair's Rounds McMaster University "ONJ and Controversies in Care"*
Hamilton, Ontario

November 12, 2012 *Osteoporosis Public Forum "New Research and Advances in Osteoporosis Therapy"*
Oakville, Ontario

January, 2013 *Medscape - Managing Hypoparathyroidism Today*
New York, New York

January 29, 2013 *Center of Excellence in Skeletal Health Assessment (CESHA) "Neurological Disorders and their Effects on Bone Health"*
University of Toronto, Ontario

February 2013 *Department of Medicine Rounds*
Windsor, Ontario

February 14, 2013 *Western University Schulich School of Medicine and Dentistry - Endocrinology Grand Rounds "Update on Osteoporosis - Key Abstracts from the ASBMR Meeting 2012"*
London, Ontario

March 2-3, 2013 *ISCD/IOF Course - Lecture 1: Overview of Osteoporosis, Lecture 4: Principles of DXA Interpretation, Clinical Management: Pharmacological Treatment, Advanced Treatment Issues*
Edmonton, Alberta

March 20, 2013 *Queen's University - Osteoporosis 2013 - Closing the Care Gap - A Review of the 2010 Osteoporosis Guidelines*
Kingston, Ontario

March 22, 2013 *International Society for Clinical Densitometry Annual Scientific Meeting - Medical Management of PHPT - Role and Options*
Tampa, Florida

March 31, 2013 *Saudi Osteoporosis Society - Controversies in Care*
Jeddah, Saudi Arabia

April 5, 2013 *5th McMaster Review Course in Internal Medicine - Vitamin D: Should we all take it?*
Hamilton, Ontario

April 12, 2013 *McMaster University - Canadian Endocrine Update - Day in Endocrinology for Primary Care Providers*
Hamilton, Ontario

April 13-14 2013 *International Society for Clinical Densitometry - Osteoporosis Essentials*
Hamilton, Ontario

April 19, 2013 *9th Annual Mature Women's Health Care - Department of Obstetrics and Gynaecology*
University of Toronto, Update on Osteoporosis
Toronto, Ontario

April 26-27, 2013 *University of Western Ontario - 9th Annual Canadian Endocrine Update (CEU) & 2nd Annual*
Canadian Endocrine Review Course (CERC)
London, Ontario

May 10, 2013 *Department of Medicine - Grand Rounds "Calcium and the Heart"*
Hamilton Health Science
Hamilton, Ontario

June 6, 2013 *7th International Hypoparathyroidism Association Conference - "Improving Quality of Life in*
Hypoparathyroidism"
Rockville, Maryland

June 15-18, 2013 *The Endocrine Society - 95th Annual Meeting & Expo - Hypoparathyroidism 2013:*
Management and Improving Quality of Life and the Effects of PTH on the Disease
San Francisco, California

Sep 19-21, 2013 *4th International Workshop "The Management of Asymptomatic Primary*
Hyperparathyroidism" - Florence, Italy
"Surgery in PHPT" - Chair
"Medical Management of Primary Hyperparathyroidism: Bisphosphonates and HRT"
Member of Expert Panel - Development of 4th International Guidelines on the Management of
Asymptomatic Primary Hyperparathyroidism

October 5, 2013 *Meet the Professor Session, The American Society for Bone and Mineral Research*
Metabolism, Baltimore, Maryland "Primary Hyperparathyroidism"

October 5-7, 2013 *ASBMR Poster Presentation:*
a) *Radiographic and Histomorphometric Features in 19 Patients*
b) *International Consensus on Diagnosis and Management of Osteonecrosis of the Jaw*
c) *A randomized, Double-Blind, Placebo-Controlled study to evaluate the effects of*
Alendronate (ALN) on bone mineral density (BMD) and bone remodeling in
perimenopausal women with low BMD

October 6, 2013 *Meet the Professor Session, The American Society for Bone and Mineral Research*
Metabolism, Baltimore, Maryland "Hypoparathyroidism"

October 16, 2013 *Warren Albert Medical School of Brown University - Rhode Island*
Endocrine Grand Rounds – "Hyperparathyroidism Diagnosis and Management in 2013"

October 28, 2013 *Centre de l'osteoporose et du rhumatologie de Quebec*
Presentation "Osteoporose et Menopause: Quoi de Neuf?"

October 29, 2013 *Presentation "Dementia and Its Effects on Bone Health" - Osteoporosis Canada Webinar*

November 25, 2013 *ASBMR Presentation - Ottawa Bone Club*

January 16, 2014 *Western University Windsor Endocrine City-Wide Rounds - "ASBMR Update" Windsor, Ontario (UWO)*

January 28, 2014 *Trillium Hospital, Department of Medicine Grand Rounds "Advances in Osteoporosis Therapy"*

February 21, 2014 *Boomer Day for Family Physicians Conquering Challenges in Osteoporosis Management & Treatment*

February 26, 2014 *Trillium Hospital Family Practice Rounds "What is New in Osteoporosis Management"*

March 26, 2014 *University of Toronto Trillium Family Medicine Residences "Osteoporosis Therapy Today"*

March 28, 2014 *Niagara Health System Clinical Rounds "From Risk to Fracture: The Complexity of Bone Loss"*

April 2-5, 2014 *International Osteoporosis Foundation World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases Seville, Spain "Osteonecrosis of the Jaw – Proceedings of the International Task Force"*

April 7, 2014 *College of Physicians and Surgeons of Ontario Assessor Meeting "Quality Improvement – A New Initiative"*

April 11-12, 2014 *McMaster University Health Sciences 10th Annual Canadian Endocrine Update "Hypoparathyroidism – Impact of therapy on the disease" "Hypercalcemia"*

April 15, 2014 *St Joseph's Healthcare, McMaster University City Wide Endocrine Rounds "Hypoparathyroidism -Advances in Diagnosis and Management and Research Agenda"*

April 24, 2014 *Ontario Medical Association The Annual Meeting of the Section on Nuclear Medicine Application of DXA Technology for Fracture Risk Assessment – What is New in 2014*

May 2, 2014 *McMaster University Health Sciences Canadian Endocrine Update Day in Endocrinology for Primary Care Providers "Osteoporosis – Drug holidays, Atypical Femoral Fractures, ONJ, Which Drug and When"*

May 26, 2014 *Humber Hospital Grand Rounds "Fracture Risk Assessment"*

June 8, 2014 *International Hypoparathyroidism Association Conference Sacramento, California
Enhancing Quality of Care in Hypoparathyroidism*

June 2014 *ICE-ENDO Late Breaking Abstract
Chicago, USA
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate (ALN) on Bone Mineral Density (BMD) and Bone Turnover in Perimenopausal Women With Low BMD.*

September 15, 2014 *Phosphaturic Mesenchymal Tumour (PMT) of the Ethmoid Sinus, Confirmed with Chromogenic In-situ Hybridization for FGF23
- Poster Presentation
Houston, Texas*

September 14, 2014 *ASBMR - Houston, Texas
International ONJ Task Force - 2014 Consensus on Diagnosis and Management
"Incidence and Prevention Strategies"*

October 17, 2014 *NAMS - Washington D.C.
Premenopausal Osteoporosis - Current Diagnosis and Management*

November 11, 2014 *The 2nd International Conference on Endocrinology and Diabetes
Riyadh, Saudi Arabia
"Management of Hypoparathyroidism: Current Issues & Advances"*

November 12, 2014 *The 2nd International Conference on Endocrinology and Diabetes
Riyadh, Saudi Arabia
"Osteoporosis: Controversies Related to Current Therapies"*

January 8, 2015 *Grand Rounds Credit Valley Hospital , University of Toronto " Atypical Femoral Fractures"*

January 13, 2015 *Grand Medical Rounds , Trillium Health Center, University of Toronto " ASBMR Update"*

February 2015 *Family Practice Grand Rounds, Trillium Health Center , University of Toronto "What's New In
Osteoporosis "*

February 28, 2015 *Meet the Professor Session " ONJ 2015" ISCD annual Scientific Meeting, Chicago , Illinois*

March 6, 2015 *Meet the Professor Session " ONJ International Consensus " The Endocrine Society, San
Diego, California*

March 25, 2015 *Endocrine Grand Rounds – Sloan Kettering Cancer Center and Cornell University
Hypoparathyroidism – Diagnosis and Management in 2015*

March 26, 2015 *7th McMaster University Review Course in Internal Medicine " Osteoporosis Update "*

April 10, 2015 *3rd Day in Endocrinology for Primary Care Providers by CEU McMaster University
"Hypercalcemia – Diagnosis and Management "*

April 25, 2015 *11th Canadian Endocrine Update University of Western Ontario , London "PHPT"*

May 2-3, 2015 *Osteoporosis Essentials Riyadh, Saudi Arabia*

May 8-9, 2015 Chair 1st International Conference on the Diagnosis , Management and Treatment of Hypoparathyroidism , Florence Italy
Podium presentation “ Magnesium homeostasis and impact on Parathyroid physiology “ Florence Italy

June 4 – 5 2015 9th International Hypoparathyroidism Association Meeting , Minneapolis , US
“ PTH therapy : Pros and Cons of therapy “

June 2015 Welland General Hospital “ Long term antiresorptive therapy : Risks and Benefits “

June 16, 2015 Endocrine City wide Grand Rounds McMaster University “ Atypical Femoral Fractures and ONJ – what you need to know about long term osteoporosis therapy “

June 30, 2015 Halton Healthcare Services CME Rounds “ The New Fracture Liaison Service at HHS- Identifying fragility fractures early “

September 13 2015 – SIGMA 2nd Annual Conference Toronto “ Osteoporosis Update” and “ premenopausal osteoporosis”

December 7, 2015 – International Osteoporosis Foundation (IOF) Meeting Abu Dhabi , United Arab Emirates
Plenary Symposia – “Challenges with Osteoporosis Therapy – Long Term Benefits and Risk “

December 20- 21, 2015 – IOF and ISCD Bone Densitometry Certification Course – Chair and Faculty
Jeddah , Saudi Arabia

January 7 , 2016 – McMaster University Grand Medical Rounds “ Osteoporosis Management – State of the Art”

January 12, 2016 Trillium Grand Medical Rounds “ Osteoporosis Diagnosis and Treatment – Advances in Research”
April 8, 2016 Chair and speaker at Day in Endocrinology Western University and McMaster University “ Osteoporosis Therapy risks and benefits “

April 16, 2016 – Canadian Association of Radiologists Annual Scientific Meeting in Montreal – podium presentation
“ Atypical Femoral Fractures – Pathophysiology , Diagnosis and AFF Alert Program “

April 29, 2016 Chair and Speaker , Canadian Endocrine Update McMaster University and Western University
“Medical Management of Primary Hyperparathyroidism “

April 30, 2016 Speaker , Canadian Endocrine Review Course , McMaster University and Western University
“ Secondary Causes of Osteoporosis”

May 4, 2016 Brampton Civic Hospital Grand Rounds “ State of the Art Osteoporosis Therapy “

June 3, 2016 10th International Hypoparathyroidism Society Meeting , Jacksonville, Florida
“ State of the Art in the Management of Hypoparathyroidism “

October 14, 2016 “ Parathyroid Bone Disease” – Canadian Musculoskeletal Conference 2016

October 15 16, 2016 International Osteoporosis Foundation – Osteoporosis Essentials Toronto , Canada

November 11, 2016 “Primary Hyperparathyroidism – new guidelines “ Medical Grand Rounds, Halton Healthcare

November 17, 2016 “ Primary Hyperparathyroidism – international consensus “ Chair’s Grand Rounds , McMaster University Medical Center

December 16-17, 2016 American Association of Clinical Endocrinologists Osteoporosis Essentials Certification

Course , Dubai, UAE

February 1, 2017 Grand Endocrine Rounds, London, Ontario, “ New Anabolic Agents , Renal Osteodystrophy and PHPT”

March 4, 2017 – Ontario Association of Medical Radiation Technologists –Education Day
“ Osteoporosis Diagnosis and Pitfalls in Interpretation of DXA “

March 7th, 2017 CLINICAL ENDOCRINOLOGY South West Ontario Primary Hyperparathyroidism - New Canadian and International Consensus 2017

April 7, 2017 Day in Endocrinology , McMaster University and Western University
Co-Chair and speaker “ Hypercalcemia – Diagnosis and Management”

April 8, 2017 7th Annual Erie St. Clair Endocrine Clinical Update – Windsor , Ontario
“Primary Hyperparathyroidism – new guidelines in 2017”

April 10, 2017 Geriatric General Rounds, McMaster University “ Primary Hyperparathyroidism 2017 – New Guidelines “

April 21, 2017 Co-Chair and Speaker “ PHPT – New Guidelines “ Canadian Endocrine Update
London, Ontario

April 21, 2017 Mature Women’s Health Care , University of Toronto, Mt Sinai Hospital
“ Osteoporosis – State of the Art 2017 “

May 13, 2017 International Hypoparathyroidism Association - Key note address “ Hypoparathyroidism diagnosis and management : State of the Art “ Buffalo New York

June 17 , 2017 “ Emerging Therapies in Bone Formation” Canadian Association of Orthopedics, Ottawa

September 8, 2017 “ Hypophosphatasia – Canadian Recommendations for Diagnosis and Treatment” Denver ,
Colorado

September 19, 2017 “ Hypophosphatasia – advances in diagnosis and management “ City Wide Endocrine Rounds
McMaster University

October 15, 2017 PER Medical Cross Fire – Hypoparathyroidism Medical Management New Jersey

October 22, 2017 “ Primary Hyperparathyroidism – Difficult Cases” Endocrine Society and the European Society of
Endocrinology – Endobridge Antalya, Turkey

November 1-4, 2017 Canadian Society of Endocrinology and Metabolism, Edmonton – plenary session “ New
International Guidelines on Primary Hyperparathyroidism “

February 20, 2018- Fifth International Conference of Endocrinology and Diabetes
– plenary sessions–Riyadh, Saudi Arabia
“Management of hypoparathyroidism- State of the Art”
“Calcium Emergencies- Diagnosis and Treatment”
“Update in Osteoporosis Management”

March 19, 2018 The Endocrine Society 100th Annual Meeting , Chicago, Illinois – Parathyroid Summit
Co-Chair and Podium presentation “ Hypoparathyroidism – Management during pregnancy “

March 22, 2018 *Internal Medicine Review Course , McMaster University “ Update on hyperparathyroidism”*

April 13, 2018 *Canadian Endocrine Update – Day in Endocrinology for primary care – Hamilton
Co-Chair*

*“ osteoporosis – how to treat and how to avoid complications”
“how to examine the thyroid gland “*

April 20, 2018 *Canadian Endocrine Update – Chair and speaker “Anabolic therapies for osteoporosis”*

April 21, 2018 *Canadian Endocrine Review Course – Speaker “ premenopausal osteoporosis “*

June 7,8 2018 *Plenary speaker International Menopause Society Meeting , Vancouver
“Prevention of osteoporosis –global strategies “*

September 2018, 28- chair , symposia on adverse effects of drug therapy , American Society of Bone and Mineral Research , Montreal , Canada

Plenary poster – Hypoparathyroidism – Diagnosis, Management and Complications – Results from the Canadian National Hypoparathyroidism Registry

October 11, 2018- 2nd International Symposia on Hypoparathyroidism – Podium presentation on “ Hypoparathyroidism and pregnancy – Diagnosis and Management “ Prague, Czech Republic

October 13, 2018 - Debate “ Anabolic therapy as first line treatment for osteoporosis at high fracture risk “
Canadian Society of Endocrinology and Metabolism , Halifax, Nova Scotia

November 12, 2018 - plenary presentation “ Advances in anabolic therapy “ KOC University School of Medicine, Istanbul , Turkey

Qatar International Osteoporosis Foundation and International Society of Clinical Densitometry Certification Course
Faculty - Doha – November 16-17, 2018

November 18, 2018- Kuwait Osteoporosis Society Scientific Symposia – Advances in Osteoporosis Management

December 11, 2018- Trillium Hospital Grand Medical Rounds – Advances in Osteoporosis Diagnosis and treatment

December 14, 2018 Rheumatology Grand Rounds , Western University , London , Ontario “ New Advances in Osteoporosis Diagnosis and Management “

January 15, 2019 - McMaster University Endocrine City Wide Rounds : Calcium Disorders in Pregnancy

February 13, 2019 – McMaster University Geriatric Grand Rounds – Standards of Care for Hypoparathyroidism

March 28, 2019 - McMaster University Internal Medicine Review Course – “ Osteoporosis Update “

April 12, 2019 – Day in Endocrinology for Primary Care Providers – McMaster University

April 26,2019 - Co-Chair , Canadian Endocrine Update – London, Ontario “ Hypophosphatasia “
“ Hypoparathyroidism – advances in management “

April 27, 2019 - Canadian Endocrine Review Course – London , Ontario “ Primary hyperparathyroidism 2019”

September 22, 2019 “ X-linked Hypophosphatemia – Advances in diagnosis and management – Satellite symposia at the American Society of Bone Mineral Research meeting in Orlando , Florida

September 23, 2019 “ Hypoparathyroidism – new advances in research “ – Satellite symposia at the American Society

of Bone Mineral Research meeting in Orlando , Florida

September 21, 2019 – session Chair the American Society of Bone Mineral Research meeting in Orlando , Florida

October 3, 2019 – Canadian Society of Endocrinology and Metabolism annual scientific meeting – plenary session speaker on “ New Guidelines for Hypoparathyroidism “

October 26 , 2019 – ISCD –IOF BMD certification course and Canadian Update on MSK Imaging Chair and speaker , St Joseph’s Healthcare, Hamilton

October 25, 2019 – Canadian Menopause Society annual Scientific Meeting Toronto , Canada Plenary session speaker – “Osteoporosis Diagnosis and Management “

December 3, 2019 -Trillium Grand Medical Rounds – “ Anabolic therapy and advances in osteoporosis “

January 22, 2020 Western University Grand Endocrine Rounds, London “ Rare Bone Diseases, Atypical Femoral Fractures , DXA technology – applications and limitations “

February 1, 2020 UOSSM (Union des Organizations de Secours et Soins Medicaux)Primary Care Update – Advances in Osteoporosis

February 25, 2020 International Osteoporosis Foundation Webinar “ Hypoparathyroidism Diagnosis and Management in 2020 “

March 4, 2020 Humber River Hospital Grand Rounds “osteoporosis – a practical approach “

June 1, 2020 – Osteoporosis Canada National CME webinar “ COVID 19 and treatment of osteoporosis “

June 12, 2020 Webinar “ Hypophosphatasia Enzyme Replacement therapy” Soft Bones Canada – national webinar

June 16, 2020 Regional Endocrine City Wide Rounds – McMaster University “ Osteoporosis Diagnosis and Management during the COVID 19 pandemic “

September 13 , 2020 – Moderator “ –Novel Therapies for Rare Bone Disease “ American Society of Bone and Mineral Research

September 15 , 2020 – Speaker – “Results of the PaTH Forward Phase 2 Trial Demonstrating Potential of Transcon PTH as a Replacement Therapy for Hypoparathyroidism ASBMR Virtual Scientific Meeting

September 17, 2020 Invited Guest Speaker Boy Frame Lecturer Henry Ford Medical Grand Rounds

September 29, 2020 ASBMR Meet The Professor Session “ Evaluation and Management of Hypoparathyroidism in 2020”

October 9,2020- Chair and speaker for Day in Endocrinology by Canadian Endocrine Update – McMaster University and Western University – lecture on “ Anabolic agents in 2020 “

October 23, 2020 - London Rheumatology Rounds – Western University – “ Anabolic therapy and advances in the treatment of osteoporosis “

October 24, 2020 – International Conference on Hypoparathyroidism – “ PTH replacement therapy – advances in medical management “

November 14, 2020 - Canadian Symposia on Rare Bone Diseases 2020 , McMaster University – Chair and speaker –

November 21, 2020 - Global Expert Summit on Hypoparathyroidism – Chair and speaker – new guidelines for hypoparathyroidism – Italy – virtual program

January 20, 2021 - Endocrine Grand Rounds , Western University – Sequential therapy for osteoporosis

February 2021- 8th International Conference of Saudi Society of Endocrinology and Metabolism
- Premenopausal osteoporosis
- Glucocorticoid Induced osteoporosis

February 2021- UOSSM (Union des Organizations de Secours et Soins Medicaux)Primary Care Update – Advances in Osteoporosis

Feb 25, 2021 – Internal Medicine Update -McMaster University – Osteoporosis a Practical Approach

March 23, 2021 – Endocrine Society Virtual Meeting
- Chair CME session on Hypoparathyroidism
- Podium presentation – “ Emerging therapies for Hypoparathyroidism and the Path Phase 1 and Phase 2 trials “

March 31, 2021 – Saudi Osteoporosis Society Annual Scientific Meeting – virtual podium presentation “ premenopausal osteoporosis and cancer related bone loss”

April 9-2021 Chair and Speaker – Canadian Endocrine Update “ X-linked hypophosphatemia – advances in diagnosis and management – McMaster University and Western

April 10- 2021 Speaker – Canadian Endocrine Review Course – “Osteoporosis – What is new “

April 10-, 2021- Chair and Speaker – ISCD- IOF – Osteoporosis Essentials Course in partnership with Osteoporosis Canada, Canadian Association of Radiology and Canadian Association of Nuclear Medicine
– Chair and Speaker – Overview of Osteoporosis and Diagnosis of Osteoporosis

April 17-18, 2021 – Quality Bone Densitometry for Clinicians -An Osteoporosis Essentials Course of the International Society for Clinical Densitometry and International Osteoporosis Foundation
Speaker – Principles of DXA Interpretation
Speaker – How to Diagnose Osteoporosis
Chair – Clinical Evaluation of Bone Health and Fracture Risk
Speaker – Case Discussions

May 26, 2021 – Chair – Symposia 25- Parathyroid Disorders – 23rd European Congress of Endocrinology 2021

June 2, 2021 –Western University - London Nephrology Rounds – Renal complications of X-Linked Hypophosphatemia

June 4, 2021 -Royal College of Obstetricians and Gynecologists of Jordan Scientific Symposia –“Advances in Osteoporosis “

August 26, 2021 London, UK – International Osteoporosis Foundation – Symposia Speaker “ State of the Art for the Diagnosis of Hypophosphatasia “

September 10, 2021 – Saudi Arabia – Osteoporosis Society – Podium Speaker – “ International Guidelines on Osteoporosis and the Role of Romosozumab “

September 17, 2021 – Queen’s University – City Wide Endocrine Rounds – speaker “ Evaluation and Management of Hypophosphatemia”

October 3, 2021 -American Society of Bone and Mineral Research – Symposia Speaker –“ New Guidelines for Hypoparathyroidism”

October 4, 2021 – American Society of Bone and Mineral Research – Speaker – “ Transcon PTH and Durable effects upto 58 weeks of the Path Forward Trial”

October 12, 2021 -Bone Health TeleECHO – “ New Guidelines for parathyroid disease “

October 22, 2021 – Day in Endocrinology – Canadian Endocrine Update by McMaster University and Western University – “ Hypercalcemia – diagnosis and management “

October 24, 2021 -Endobridge – joint program by European Society of Endocrinology and Endocrine Society “Update on Hypoparathyroidism”

October 29, 2021 – Society of Obstetricians and Gynecologists of Canada – “ New SOGC Guidelines for Osteoporosis” – virtual Canada wide symposia

October 30, 2021 – Saudi Osteoporosis Society – Osteoporosis Awareness Day- “ Premenopausal Osteoporosis “

November 5, 2021 – Canadian Symposia on Rare Bone Diseases 2021 – Chair and Speaker “XLH – Diagnosis and Management in Adults “

November 9, 2021- University of Ottawa, Endocrine Club –“ ASBMR Update 2021”

November 12, 2021 -American Association of Clinical Endocrinologists Scientific program –“ Hyperparathyroidism”

November 15, 2021 Makkah Endocrine Club “ Advances in Anabolic Therapy 2021”

November 20, 2021 Canadian Musculoskeletal Conference – Osteoporosis Canada and University of Toronto “ Discontinuation of denosumab – when and how “

November 30, 2021 -Bone Health ECHO – USA – “ Hypoparathyroidism Guidelines “

December 3, 2021 Global Expert Summit on Hypoparathyroidism – virtual symposia “ New Guidelines for Hypoparathyroidism “

December 9, 2021- XV1 OrtoMed Societa Italiana di Ortopedia Medicina e delle Mallattie Rare dello Scheletro -plenary speaker “ New Diagnostic Criteria for Hypophosphatasia”

Feb 8, 2022 – University of Ottawa Endocrinology Journal Club – “ New Guidelines for Primary Hyperparathyroidism”

February 15, 2022- Kuwait Rheumatology Symposia –“New drugs for Osteoporosis”

February 18,2022 – Family Practice Rounds -Michael Garron Rounds –“Anabolic therapy for osteoporosis”

March 10, 2022 – Metabolic Bone Disease Symposia – Kingdom of Saudi Arabia “ New Guidelines for Hypoparathyroidism “

April 1, 2022 – Canadian Endocrine Update –Chair and Speaker - Parathyroid disease in pregnancy – University of Western Ontario

April 2, 2022 – Canadian Endocrine Review Course – Normocalcemic hyperparathyroidism -New Guidelines – University of Western Ontario

May 10, 2022 – University of Ottawa Endocrine Rounds – New SOGC Guidelines for osteoporosis

May 12, 2022 – American Association of Clinical Endocrinologists – Symposia speaker “ New Guidelines for Primary Hyperparathyroidism

June 8, 2022 – Quebec City Endocrine Rounds – “X- Linked Hypophosphatemia “

June 12 , 2022 – Endocrine Society Annual Meeting – Atlanta ,USA

- Master Clinician Session Speaker “ Hypoparathyroidism New Global Guidelines “

- Late breaking oral presentation “ Phase 3 Pathway Trial -participants treated with TransCon PTH achieved independence from conventional therapy while maintaining normal serum calcium

- Outstanding abstract award supervisor “ Transition From Low Dose Denosumab 30mg to IV Zoledronic Acid: Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Prospective Observational Study” by Dalal Ali and Aliya Khan

June 28, 2022 – CSEM Knowledge Translation Activity on Hypocalcemia – speaker

June 29, 2022 – Gulf Association of Endocrinology and Diabetes GAED – speaker – “ New Guidelines on Hypoparathyroidism”

August 26, 2022 – International Society of Endocrinology – Symposia speaker – Parathyroid Disease and impact on Skeletal Health”

August 26, 2022 – International Society of Endocrinology – Singapore – Chair – Chronic Kidney disease and metabolic bone disease

September 8, 2022 – Clinical Endocrine Update by Endocrine Society – Speaker – New Global Guidelines for PHPT and HypoPT

September 8, 2022 – Clinical Endocrine Update by Endocrine Society – Ancillary Symposia Speaker -Management of Hypoparathyroidism

September 14, 2022 -15th International Congress of the Jordanian Society of Obstetricians & Gynecologists - new guidelines for osteoporosis

September 21, 2022 – City wide Endocrine Rounds McMaster University – New Global Parathyroid Guidelines 2022

September 22, 2022 – Osteoporosis Canada Beyond the Break – Anabolic therapy for osteoporosis

September 23, 2022 – Chair and speaker -Day in Endocrinology McMaster University and Western University –“ SOGC guidelines for Osteoporosis 2022”

September 30, 2022 – Speaker at University of Toronto City Wide Endocrine Rounds “ New Global Guidelines on Parathyroid Disease “

October 13, 2022 -Speaker at McMaster Internal Medicine Update “ Hypercalcemia”

October 14,2022 – Chair American Society of Bone and Mineral Research Adult Bone and Mineral Working Group 2022

October 21, 2022 – Speaker at International Hypoparathyroidism Association Annual meeting “New Global Guidelines for Hypoparathyroidism”

October 28, 2022 – Speaker at Endocrine Grand Rounds Washington University School of Medicine “Global Guidelines for Hypoparathyroidism”

Dec 2, 2022 – Chair and Speaker 3rd Canadian Symposia on Rare Bone Diseases “Hypophosphatasia – new diagnostic criteria”

Dec 3, 2022 – Chair and Speaker – ISCD-IOF Osteoporosis Essentials Bone Densitometry course

Dec 15, 2022 XVII ORTOMED CONGRESS, Florence (Italy) Podium presentation “Antiresorptive therapy and impact on dental implant survival”

February 8 2023- Endocrine Grand Rounds – Western University , London “ Hypophosphatasia – advances in therapy”

February 9, 2023 – Endocrine Grand Rounds – Windsor “ advances in diagnosis and management”

February 11 , 2023- UOSSM -5th annual Primary care update in partnership with McMaster University – Chair and speaker “ calcium emergencies”

February 20, 2023- Advances in Hypoparathyroidism – Calcium and Metabolic Bone Program at American University of Beirut. Lebanon

February 22, 2023 – Royal United Hospital , National Health Service, Bath, United Kingdom “ Management of Parathyroid Disease in Pregnancy”

March 1, 2023 -" Endocrine Grand Rounds at Harvard University -Brigham and Womens Hospital " - New Global Guidelines for parathyroid disease

March 1, 2023 – “ Anabolic molecules for osteoporosis” -West Coast Bone Health CME TeleECHO: Spokane Strides For Strong Bones

March 3, 2023 –“New Global guidelines for Parathyroid Disease” MD Anderson, Houston Texas Multidisciplinary Parathyroid Neoplasia Grand Rounds

March 9, 2023 – Grand Rounds McMaster University “ Global Guidelines for Parathyroid Disease”

10TH SKELETAL ENDOCRINOLOGY MEETING
26th/27th MARCH 2023 – ITALY- Novel molecules for the treatment of hypoparathyroidism

March 2023- Halton Healthcare Dept of Medicine Rounds – “ New Guidelines for parathyroid disease”

April 14, 2023- Mature Womens Health Care University of Toronto “ new SOGC guidelines for osteoporosis “
April 14, 2023- Canadian Geriatric Society Annual Scientific Meeting – Vancouver – “ New Canadian Position paper on post fracture care “

April 21, 2023 – Chair and Speaker – Canadian Endocrine Update –“ New Global Guidelines on Parathyroid Disease”

April 22, 2023 – Speaker – Canadian Endocrine Review Course – “ New Osteoporosis Guidelines and Role of Anabolic Therapy “

May 5, 2023- speaker – International Osteoporosis Foundation Meeting in Barcelona, Spain – Meet the Professor session – “New Guidelines for Hyperparathyroidism”

May 6, 2023- speaker – International Osteoporosis Foundation Meeting in Barcelona, Spain – Podium presentation – “New Guidelines for Osteonecrosis of the Jaw “

May 25, 2023 speaker – Hypoparathyroidism Global Guidelines 2023- Egyptian Society of Endocrinology ESEO 23

May 25, 2023 – Speaker – McMaster University Internal Medicine Update “ vertebral fractures – how to investigate and treat “

May 25, 2023 – Speaker – Canadian Society of Endocrinology and Metabolism Knowledge Translation Webinar on Osteoporosis Update

May 27, 2023- Plenary Speaker – Second Arab Thyroid Association Scientific Symposia – Dubai
“Primary Hyperparathyroidism – New Global Guidelines “

June 13, 2023 – Speaker “ Update on Palopegteriparatide for Hypoparathyroidism” at the 5th International Calcium Sensing Receptor Meeting in Chicago in conjunction with The Endocrine Society Meeting

June 15, 2023 – Chair “ Hypercalcemia Guidelines “ at The Endocrine Society Meeting , Chicago

August 18, 2023 – Speaker “ Management of Hypoparathyroidism – present and emerging therapies” Argentinian Association of Bone and Mineral Metabolism (AAOMM) and Argentinian Society of Osteoporosis (SAO) 6th Congreso Conjunto Argentino de Osteoporosis 2023

September 9, 2023 – Plenary session speaker “ New Diagnostic Criteria for Hypophosphatasia” Society of Endocrinology and Metabolism and Diabetes of South Africa (SEMDSA) Annual Scientific Meeting

September 10, 2023 – Speaker “ New Global Guidelines for Hypoparathyroidism” SEMDSA Annual Scientific Meeting

September 22, 2023 – Chair and Speaker – Day in Endocrinology by Canadian Endocrine Update – McMaster University and Western University “ Hypercalcemia – how to diagnose and treat”

October 6, 2023 – University of Toronto City Wide Endocrine Rounds – “ Hypercalcemia of Malignancy – State of the Art in Diagnosis and Management”

Oct 13-15, 2023 – American Society of Bone and Mineral Research Annual Scientific Meeting – Vancouver
Podium presentation – XLH – new advances for diagnosis and therapy
Podium presentation – Hypoparathyroidism – new guidelines for management
Podium presentation – biosimilar therapies for osteoporosis
Podium presentation - Improved Skeletal Dynamics in Adults Treated With Palopegteriparatide for Hypoparathyroidism: 52-Week Analysis of Phase 3 PaTHway Trial

October 20, 2023 – Endobridge Plenary Session “New Guidelines on Hypoparathyroidism” Antalya Turkey

October 28, 2023- Endocrine Rounds Jeddah , Saudi Arabia “ Anabolic Therapy and Fracture Risk Reduction”

October 30, 2023 – Endocrine Rounds Madina, Saudi Arabia “ Post Fracture Care – Evidence based approach”

October 28, 2023 – ECTS – European Calcified Tissue Society – Webinar “ Treatment of Hypoparathyroidism in the Western World”

Jan 16, 2024 – International Menopause Society webinar – “ Options for treatment including estrogen , new therapeutic options and possible protection after menopause

Jan 17, 2024 – Western University Endocrine Rounds “ Post hip fracture care guidelines”

March 13, 2024 – Academic Half Day – McMaster University Radiology Department

April 12, 2024- International Osteoporosis Foundation Annual meeting in London UK “New Diagnostic Criteria for Hypophosphatasia “

April 16 2024- Egyptian Society of Metabolic Syndrome (ESMA) International Meeting 2024- New Guidelines for Primary Hyperparathyroidism

April 17 ,2024 - 45th Turkish Endocrinology and Metabolism Diseases Congress- New Guidelines for Osteoporosis - Role of Anabolic Therapy”

May 15, 2024 – Emerging therapies for Hypoparathyroidism – National Health Service, London, UK

May 25, 2024- Plenary Session European Calcified Tissue Society 51st Annual Scientific Symposia Marseilles, France “ DXA Best Practice – Guidelines from the International Working Group “

May 28, 2024 - Plenary Oral Session European Calcified Tissue Society 51st Annual Scientific Symposia “ Improved skeletal dynamics in adults treated with palopegteriparatide (TransCon PTH) for hypoparathyroidism: 52-week analysis of phase 3 PaTHway trial”

May 31, 2024- Co-Chair and plenary speaker, Parathyroid Summit, Endocrine Society Pre-meeting, Boston

June 1, 2024- Symposia speaker, Emerging Therapies for Hypoparathyroidism , Endocrine Society meeting Boston

June 4, 2024 – Meet the Professor Session, The Many Faces of Hyperparathyroidism, Endocrine Society meeting , Boston

June 11, 2024 – Windsor Orthopedic Rounds – Post Hip Fracture Care

June 28, 2024- Endocrine Rounds ,Dalhousie University, “ Hypophosphatemia – Evaluation and Management “ Halifax, Nova Scotia

June 11, 2024 – Windsor Orthopedic Rounds – Post Hip Fracture Care

June 28, 2024- Endocrine Rounds ,Dalhousie University, “ Hypophosphatemia – Evaluation and Management “ Halifax, Nova Scotia

September 28- October 1 2024 -American Society of Bone and Mineral Research, Toronto
podium presentations
International Guidelines for X-Linked Hypophosphatemia
Diagnostic Criteria for Hypophosphatasia
Advances in Hypoparathyroidism
Co-Chair – Adult Bone and Mineral Working Group
Meet the Professor – Hypoparathyroidism

October 7, 2024 CaMOP American University of Beirut "AFF, ONJ, and other OP Drug-induced Complications"

October 25, 2024 Hypoparathyroidism Global Guidelines -Romanian Endocrine Society, Bucharest, Romania

October 31, 2024 – 5th International Annual Conference of The Egyptian Academy of Bone Health and Metabolic Bone Diseases in collaboration with the IOF “New Guidelines for Osteoporosis and Role of Anabolic Therapy” Cairo, Egypt

November 2, 2024 – Hypoparathyroidism Association – Washington, USA, Global Guidelines for Hypoparathyroidism

November 11, 2024- Endocrine Society Of Australia, Sydney Australia – PTH Replacement for Hypoparathyroidism

November 13, 2024- Cleveland Clinic , Cleveland, Ohio– International Guidelines on Hypoparathyroidism

November 14, 2024 -Swiss Society for Endocrinology and Diabetology (SSED) Annual Scientific Meeting Berne, Switzerland “Efficacy and safety of Hormone Replacement with Transcon PTH in Hypoparathyroidism”

November 22, 2024 Halifax DR. JACQUES GENEST LECTURER AWARD RECIPIENT : Aliya A. Khan: Awarded to the individual chosen to deliver the Canadian Society of Endocrinology and Metabolism Award Lecture at the Annual Professional Conference

November 29, 2024- Canadian Symposia on Rare Bone Diseases in partnership with the Canadian Society of Endocrinology and Metabolism (CSEM) and the Canadian Society of Nuclear Medicine (CANM) -Chair and speaker “ Hypoparathyroidism – Novel therapies “

November 30, 2024 – Osteoporosis Essentials -BMD certification course by the ISCD and IOF in partnership with CSEM and CANM – Chair and speaker

December 6, 2024 - 145th IVPN-AR "From Challenges to Solutions: Advancements in Chronic Hypoparathyroidism Care" Kingdom of Saudi Arabia

December 12, 2024 – Florence, Italy –at 19th Annual OrtoMed Symposia Societa Italiana di Ortopedia, Medicina e delle Malattie Rare dello Scheletro “Hypoparathyroidism – Past, Present and Future”

December 13, 2024- Florence, Italy – at 19th Annual OrtoMed Symposia Societa Italiana di Ortopedia, Medicina e delle Malattie Rare dello Scheletro “ International X- Linked Hypophosphatemia Guidelines for Diagnosis and Management 2025”

January 26, 2025 “Calcium Conundrums”
60th Annual Clinical Diabetes and Endocrinology Institute (CDEI) CME Conference Vail, Colorado, USA

January 27, 2025 “Postmenopausal Osteoporosis”
60th Annual Clinical Diabetes and Endocrinology Institute (CDEI) CME Conference Vail, Colorado, USA

February 5, 2025 – Western Endocrine Rounds “X-Linked Hypophosphatemia “

February 20,2025 – McMaster University Internal Medicine Review Course –“hypo and hypercalcemia diagnosis and management “

February 26, 2025 -Egyptian Society of Metabolic Syndrome International Meeting –“Hypoparathyroidism Global Guidelines “

March 14, 2025 -11th Skeletal Endocrinology Scientific Meeting, Trento , Italy – “Hypoparathyroidism – Approved and Emerging therapies”

MEDIA PRESENTATIONS:

October 2024- Medscape – Hypoparathyroidism and bone

June 2024- Medscape – Hypophosphatasia – New Diagnostic criteria

June 2024- Medscape – Hypophosphatasia – New Diagnostic criteria
 June 2023 – Medscape – Hypoparathyroidism – the patient journey
 Jan 2023 – Medscape – Advances in Rare Bone Diseases
 July 2022 – Medscape “ New Guidelines for Hypoparathyroidism “
 April 2022- Medscape Education Program, "Disorders of Low Parathyroid Hormone: Do You Recall Where Autosomal Dominant Hypocalcemia Type 1 Fits?" : https://www.medscape.org/viewarticle/972369_2
 OCTOBER 19, 2021 MEDSCAPE -NEW GUIDELINES FOR HYPOPARATHYROIDISM
 March 2021 – Medscape- Tricky Cases in Metabolic Bone Disease: How to Catch Them Earlier
 Authors: Aliya Khan, MD, FRCPC, FACP, FACE; Pablo Florenzano, MD, PhD; Kassim Javaid, MBBS, BMedSci, MRCP, PhD Faculty and Disclosures. CPD Released: 3/26/2021
 NOV 2020 XLH and you – ctv- health and family
 MEDSCAPE – Hypoparathyroidism And Stopping Pth January 2020
 Reality check: not just women are affected by osteoporosis. We're all at risk.
 You are UNLTD Nov 12, 2019
 Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvida™ (burosumab injection) for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children
 PharmiWeb.com (12/6/2018)
 Medscape Medical News © 2018 WebMD, LLC Cite this article: Beyond 2 Years, Oral Bisphosphonate Holiday Ups Broken Hip Risk - Medscape - Oct 01, 2018
 OSTEOPOROSIS IS A MEN'S DISEASE, TOO: WHAT AN EXPERT HAS TO SAY
 By: Doug O'Neill. July 10, 2018 Your are UNLTD
 CBC News May 31, 2017 “ New program for osteoporosis in Windsor”
 CTV News May 31, 2017 “ Screening program for osteoporosis improves treatment”
 Windsor Star May 31, 2017 Screening process for osteoporosis a boost in bone care, doctor says
 Toronto Star November 28, 2016 ' Family overwhelmed with gratitude " "
 Toronto Star November 1, 2015 " A word from the Sponsors'
 Bill Kelly Radio “ Syrian Refugees and the global humanitarian response “ September 8, 2015
 Toronto Star “ Refugees International “ September 11, 2015
 CTV News "Calcium and Mortality Rates" - May 26, 2013
 CBC News Radio “Menopause” November 8, 2012
 Globe and Mail “Osteoporosis Drugs May Not Be Best Choice” June 13, 2012
 Oakville Beaver “Oakvillians Honoured with Diamond Jubilee Medal” June 3, 2012
 CBC National “Calcium Supplement Use May Raise Heart Attack Risk” May 23, 2012
 Oakville Beaver “Doctor Recognized Internationally” April 20, 2012
 CTV Canadian Health & Family “Living with and Managing Osteoporosis”, November 19, 2011
 Canadian Living, “New Treatment for Osteoporosis”, September 2011
 Hamilton Spectator, “Osteoporosis Drug linked to bone fractures”, October 15, 2010
 Toronto Star, “Osteonecrosis of the Jaw”, October 15, 2010
 Toronto Star, “Bone density test key to prevention”, June 2009
 Hamilton Health Fair, Talk 820 radio, Friday February 13, 2009
 Jamie West Show at 12 noon, February 5, 2009
 CTV National Live 9:15 am, “HRT New data regarding safety,” January 23, 2009
 CBC Radio, “New Guidelines for HRT,” January 23, 2009
 The Globe and Mail, “Bone Drug Controversy,” June 13, 2008
 February 13, 2008 CHAM Live Doctors for Humanity Public Symposia
 Hamilton Wave Radio “ Osteoporosis in Men “ Oct 15, 2007
 CFRB-1010AM, “ Osteoporosis in Men “ March 25, 2007 2pm Live
 CHOK-AM, March 19, 2007 “ Osteoporosis in men “ 11:08am Live
 CKNX-AM, March 15, 2007 “ Osteoporosis in Men “ 9:15am Live
 CKNX-AM, March 9, 2007 “ Osteoporosis in Men “ 9:15am Live
 CKPR-AM, March 5, 2007 “ Osteoporosis in Men “ 8:30am Live
 Ottawa Sun, February 12, 2007 “ Osteoporosis in Men “

CHML AM, February 12, 2007 "Osteoporosis in Men"
 AM 1020, February 12, 2007 "Osteoporosis in Men"
 CFTL AM 980, February 12, 2007 "Osteoporosis in Men"
 CTS-Channel 9, February 12, 2007 "Osteoporosis in Men",
 CP24 Talk TV, City TV "Osteoporosis in Men" February 5, 2007 5pm – 6pm Live
 Morning Live CH TV, "Vitamin D and bone health" January 30, 2007 7:15 AM interview
 Wave Radio, , "Vitamin D and bone health" January 30, 2007
 K-Lite FM, , "Vitamin D and bone health" January 30, 2007
 AM 1220, "Vitamin D and bone health", January 17, 2007 8:10am Live
 CKPC-AM, , "Vitamin D and bone health" January 12, 2007
 CHML-AM, , "Vitamin D and bone health" January 11, 2007 12:35pm Live
 CFPL-AM, , "Vitamin D and bone health" January 11, 2007 10:35am Live
 Toronto Sun, , "Vitamin D and bone health" January 10, 2007
 The Hamilton Spectator, "Bone Boosters", October 23, 2006
 CFRB Health Show Invited Guest, April 30, 2006 2pm – 3pm Live
 CHQR "Ask the Experts" Radio Calgary, April 22, 2006 5pm – 6pm Live
 CH 740 AM Invited Guest April 23, 2006 8am – 9am
 AM740 "Vitamin D and Osteoporosis" April 18, 2006 4:30pm – 6pm
 Cogeco "Round Table "Anabolic therapies in 2005" November, 2005
 CH News at 6 PM "Osteoporosis in Children", November 10, 2004
 Cogeco "Round Table on Parathyroid hormone" August 6, 2004
 CHML Radio "Parathyroid Disease" August 3, 2004 @ 7:30 AM Live
 CH News at 6 PM "Parathyroid Disease" July 14, 2004
 Diagnosis on Osteoporosis CD – multimedia presentation University of Calgary February 2004
 Bone Quality Discussion CD – multimedia presentation September 2003
 CFRB Health Show Invited Guest, February 23, 2003 2pm – 3pm Live
 Cogeco "Round Table on Osteoporosis" January 7, 2003 7pm – 8pm Live
 Miacalcin Multi Media Press Release May 2000